UFT B-Chemical +
and O +
its O +
metabolites O +
inhibit O +
the O +
angiogenesis O +
induced O +
by O +
murine O +
renal O +
cell O +
carcinoma O -
, O +
as O +
determined O +
by O +
a O +
dorsal O +
air O +
sac O +
assay O +
in O +
mice O -
. O +

UFT B-Chemical -
, O +
an O +
anticancer O +
agent O +
that O +
is O +
composed O +
of O +
tegafur B-Chemical +
( O -
FT B-Chemical -
) O +
and O +
uracil B-Chemical +
at O +
a O +
molar O +
ratio O +
of O +
1:4 O -
, O +
is O +
widely O +
used O +
in O +
clinical O +
practice O +
in O +
Japan O +
to O +
treat O +
cancer O +
patients O +
requiring O +
a O +
long O -
- O -
term O +
chemotherapy O -
, O +
and O +
it O +
is O +
associated O +
with O +
few O +
side O +
effects O -
, O +
if O +
any O -
. O +

In O +
this O +
study O -
, O +
we O +
have O +
evaluated O +
the O +
inhibitory O +
effect O +
of O +
UFT B-Chemical +
against O +
RENCA O +
cell O -
- O -
induced O +
angiogenesis O +
by O +
a O +
dorsal O +
air O +
sac O +
assay O -
. O +

Marked O +
angiogenesis O +
is O +
induced O +
by O +
implantation O +
of O +
a O +
chamber O +
containing O +
RENCA O +
cells O +
into O +
mice O -
. O +

In O +
this O +
model O -
, O +
UFT B-Chemical +
showed O +
a O +
strong O +
angiogenesis O -
- O -
inhibitory O +
effect O -
, O +
whereas O +
5-fluorouracil B-Chemical +
( O -
5-FU B-Chemical -
) O +
and O +
doxifluridine B-Chemical +
were O +
less O +
effective O -
. O +

Additional O +
experiments O +
revealed O +
FT B-Chemical +
to O +
be O +
effective O +
component O +
of O +
UFT B-Chemical -
; O +
uracil B-Chemical +
remained O +
ineffective O +
in O +
the O +
inhibition O +
of O +
angiogenesis O -
. O +

Moreover O -
, O +
we O +
have O +
found O +
that O +
gamma B-Chemical -
- I-Chemical -
hydroxybutyric I-Chemical +
acid I-Chemical +
and O +
gamma B-Chemical -
- I-Chemical -
butyrolactone I-Chemical -
, O +
the O +
metabolites O +
of O +
FT B-Chemical -
, O +
possess O +
a O +
potent O +
angiogenesis O +
inhibitory O +
effect O +
that O +
is O +
amplified O +
when O +
the O +
compounds O +
are O +
administered O +
by O +
a O +
continuous O +
infusion O -
. O +

This O +
may O +
reflect O +
a O +
transition O +
in O +
blood O +
concentration O +
of O +
each O +
metabolite O +
resulting O +
from O +
the O +
administration O +
of O +
UFT B-Chemical -
. O +

Similar O +
results O +
were O +
also O +
obtained O +
with O +
respect O +
to O +
5-FU B-Chemical -
. O +

It O +
was O +
suggested O +
that O +
UFT B-Chemical +
has O +
a O +
stronger O +
angiogenesis O -
- O -
inhibitory O +
effect O +
than O +
did O +
other O +
fluorinated B-Chemical +
pyrimidines I-Chemical -
, O +
partly O +
due O +
to O +
its O +
pharmacokinetic O +
properties O +
characterized O +
by O +
maintaining O +
of O +
higher O +
and O +
long O -
- O -
lasting O +
blood O +
levels O +
of O +
5-FU B-Chemical +
and O +
partly O +
due O +
the O +
inhibitory O +
effects O +
derived O +
from O +
gamma B-Chemical -
- I-Chemical -
hydroxybutyric I-Chemical +
acid I-Chemical +
and O +
gamma B-Chemical -
- I-Chemical -
butyrolactone I-Chemical -
, O +
UFT B-Chemical -
- O -
specific O +
metabolites O -
. O +

Regulation O +
of O +
the O +
resident O +
chromosomal O +
copy O +
of O +
c O -
- O -
myc O +
by O +
c O -
- O -
Myb O +
is O +
involved O +
in O +
myeloid O +
leukemogenesis O -
. O +

c O -
- O -
myb O +
is O +
a O +
frequent O +
target O +
of O +
retroviral O +
insertional O +
mutagenesis O +
in O +
murine O +
leukemia O +
virus O -
- O -
induced O +
myeloid O +
leukemia O -
. O +

Induction O +
of O +
the O +
leukemogenic O +
phenotype O +
is O +
generally O +
associated O +
with O +
inappropriate O +
expression O +
of O +
this O +
transcriptional O +
regulator O -
. O +

Despite O +
intensive O +
investigations O -
, O +
the O +
target O +
genes O +
of O +
c O -
- O -
myb O +
that O +
are O +
specifically O +
involved O +
in O +
development O +
of O +
these O +
myeloid O +
lineage O +
neoplasms O +
are O +
still O +
unknown O -
. O +

In O +
vitro O +
assays O +
have O +
indicated O +
that O +
c O -
- O -
myc O +
may O +
be O +
a O +
target O +
gene O +
of O +
c O -
- O -
Myb O -
; O +
however O -
, O +
regulation O +
of O +
the O +
resident O +
chromosomal O +
gene O +
has O +
not O +
yet O +
been O +
demonstrated O -
. O +

To O +
address O +
this O +
question O +
further O -
, O +
we O +
analyzed O +
the O +
expression O +
of O +
c O -
- O -
myc O +
in O +
a O +
myeloblastic O +
cell O +
line O -
, O +
M1 O -
, O +
expressing O +
a O +
conditionally O +
active O +
c O -
- O -
Myb O -
- O -
estrogen O +
receptor O +
fusion O +
protein O +
( O -
MybER O -
) O -
. O +

Activation O +
of O +
MybER O +
both O +
prevented O +
the O +
growth O +
arrest O +
induced O +
by O +
interleukin-6 O +
( O -
IL-6 O -
) O +
and O +
rapidly O +
restored O +
c O -
- O -
myc O +
expression O +
in O +
nearly O +
terminal O +
differentiated O +
cells O +
that O +
had O +
been O +
exposed O +
to O +
IL-6 O +
for O +
3 O +
days O -
. O +

Restoration O +
occurred O +
in O +
the O +
presence O +
of O +
a O +
protein O +
synthesis O +
inhibitor O +
but O +
not O +
after O +
a O +
transcriptional O +
block O -
, O +
indicating O +
that O +
c O -
- O -
myc O +
is O +
a O +
direct O -
, O +
transcriptionally O +
regulated O +
target O +
of O +
c O -
- O -
Myb O -
. O +

c O -
- O -
myc O +
is O +
a O +
major O +
target O +
that O +
transduces O +
Myb O -
's O +
proliferative O +
signal O -
, O +
as O +
shown O +
by O +
the O +
ability O +
of O +
a O +
c O -
- O -
Myc O -
- O -
estrogen O +
receptor O +
fusion O +
protein O +
alone O +
to O +
also O +
reverse O +
growth O +
arrest O +
in O +
this O +
system O -
. O +

To O +
investigate O +
the O +
possibility O +
that O +
this O +
regulatory O +
connection O +
contributes O +
to O +
Myb O -
's O +
oncogenicity O -
, O +
we O +
expressed O +
a O +
dominant O +
negative O +
Myb O +
in O +
the O +
myeloid O +
leukemic O +
cell O +
line O +
RI-4 O -
- O -
11 O -
. O +

In O +
this O +
cell O +
line O -
, O +
c O -
- O -
myb O +
is O +
activated O +
by O +
insertional O +
mutagenesis O +
and O +
can O -
not O +
be O +
effectively O +
down O +
regulated O +
by O +
cytokine O -
. O +

Myb O -
's O +
ability O +
to O +
regulate O +
c O -
- O -
myc O -
's O +
expression O +
was O +
also O +
demonstrated O +
in O +
these O +
cells O -
, O +
showing O +
a O +
mechanism O +
through O +
which O +
the O +
proto O -
- O -
oncogene O +
c O -
- O -
myb O +
can O +
exert O +
its O +
oncogenic O +
potential O +
in O +
myeloid O +
lineage O +
hematopoietic O +
cells O -
. O +

Vascular O +
proliferation O +
and O +
enhanced O +
expression O +
of O +
endothelial O +
nitric O +
oxide O +
synthase O +
in O +
human O +
peritoneum O +
exposed O +
to O +
long O -
- O -
term O +
peritoneal O +
dialysis O -
. O +

Long O -
- O -
term O +
peritoneal O +
dialysis O +
( O -
PD O -
) O +
is O +
associated O +
with O +
alterations O +
in O +
peritoneal O +
permeability O +
and O +
loss O +
of O +
ultrafiltration O -
. O +

These O +
changes O +
originate O +
from O +
increased O +
peritoneal O +
surface O +
area O -
, O +
but O +
the O +
morphologic O +
and O +
molecular O +
mechanisms O +
involved O +
remain O +
unknown O -
. O +

The O +
hypothesis O +
that O +
modifications O +
of O +
activity O +
and/or O +
expression O +
of O +
nitric O +
oxide O +
synthase O +
( O -
NOS O -
) O +
isozymes O +
might O +
play O +
a O +
role O +
in O +
these O +
modifications O -
, O +
via O +
enhanced O +
local O +
production O +
of O +
nitric B-Chemical +
oxide I-Chemical -
, O +
was O +
tested O +
in O +
this O +
study O -
. O +

NOS O +
activities O +
were O +
measured O +
by O +
the O +
L O -
- O -
citrulline O +
assay O +
in O +
peritoneal O +
biopsies O +
from O +
seven O +
control O +
subjects O -
, O +
eight O +
uremic O +
patients O +
immediately O +
before O +
the O +
onset O +
of O +
PD O -
, O +
and O +
13 O +
uremic O +
patients O +
on O +
short O -
- O -
term O +
( O +
less O +
than O +
18 O +
mo O -
, O +
n O +
= O +
6 O -
) O +
or O +
long O -
- O -
term O -
( O +
greater O +
than O +
18 O +
mo O -
, O +
n O +
= O +
7 O -
) O +
PD O -
. O +

Peritoneal O +
NOS O +
activity O +
is O +
increased O +
fivefold O +
in O +
long O -
- O -
term O +
PD O +
patients O +
compared O +
with O +
control O +
subjects O -
. O +

In O +
uremic O +
patients O -
, O +
NOS O +
activity O +
is O +
positively O +
correlated O +
with O +
the O +
duration O +
of O +
PD O -
. O +

Increased O +
NOS O +
activity O +
is O +
mediated O +
solely O +
by O +
Ca O -
( O -
2+ O -
) O -
-dependent O +
NOS O +
and O -
, O +
as O +
shown O +
by O +
immunoblotting O -
, O +
an O +
upregulation O +
of O +
endothelial O +
NOS O -
. O +

The O +
biologic O +
relevance O +
of O +
increased O +
NOS O +
in O +
long O -
- O -
term O +
PD O +
was O +
demonstrated O +
by O +
enhanced O +
nitrotyrosine B-Chemical +
immunoreactivity O +
and O +
a O +
significant O +
increase O +
in O +
vascular O +
density O +
and O +
endothelial O +
area O +
in O +
the O +
peritoneum O -
. O +

Immunoblotting O +
and O +
immunostaining O +
studies O +
demonstrated O +
an O +
upregulation O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
mostly O +
along O +
the O +
endothelium O +
lining O +
peritoneal O +
blood O +
vessels O +
in O +
long O -
- O -
term O +
PD O +
patients O -
. O +

In O +
the O +
latter O -
, O +
VEGF O +
colocalized O +
with O +
the O +
advanced O +
glycation O +
end O +
product O +
pentosidine B-Chemical +
deposits O -
. O +

These O +
data O +
provide O +
a O +
morphologic O +
( O -
angiogenesis O +
and O +
increased O +
endothelial O +
area O -
) O +
and O +
molecular O +
( O -
enhanced O +
NOS O +
activity O +
and O +
endothelial O +
NOS O +
upregulation O -
) O +
basis O +
for O +
explaining O +
the O +
permeability O +
changes O +
observed O +
in O +
long O -
- O -
term O +
PD O -
. O +

They O +
also O +
support O +
the O +
implication O +
of O +
local O +
advanced O +
glycation O +
end O +
product O +
deposits O +
and O +
liberation O +
of O +
VEGF O +
in O +
that O +
process O -
. O +

High O +
frequency O +
of O +
hypermethylation O +
at O +
the O +
14 O -
- O -
3 O -
- O -
3 O +
sigma O +
locus O +
leads O +
to O +
gene O +
silencing O +
in O +
breast O +
cancer O -
. O +

Expression O +
of O +
14 O -
- O -
3 O -
- O -
3 O +
final O +
sigma O +
( O -
final O +
sigma O -
) O +
is O +
induced O +
in O +
response O +
to O +
DNA O +
damage O -
, O +
and O +
causes O +
cells O +
to O +
arrest O +
in O +
G O -
( O -
2 O -
) O -
. O +

By O +
SAGE O +
( O -
serial O +
analysis O +
of O +
gene O +
expression O -
) O +
analysis O -
, O +
we O +
identified O +
final O +
sigma O +
as O +
a O +
gene O +
whose O +
expression O +
is O +
7-fold O +
lower O +
in O +
breast O +
carcinoma O +
cells O +
than O +
in O +
normal O +
breast O +
epithelium O -
. O +

We O +
verified O +
this O +
finding O +
by O +
Northern O +
blot O +
analysis O -
. O +

Remarkably O -
, O +
final O +
sigma O +
mRNA O +
was O +
undetectable O +
in O +
45 O +
of O +
48 O +
primary O +
breast O +
carcinomas O -
. O +

Genetic O +
alterations O +
at O +
final O +
sigma O +
such O +
as O +
loss O +
of O +
heterozygosity O +
were O +
rare O +
( O -
1 O -
/ O -
20 O +
informative O +
cases O -
) O -
, O +
and O +
no O +
mutations O +
were O +
detected O +
( O -
0 O -
/ O -
34 O -
) O -
. O +

On O +
the O +
other O +
hand O -
, O +
hypermethylation O +
of O +
CpG O +
islands O +
in O +
the O +
final O +
sigma O +
gene O +
was O +
detected O +
in O +
91 O -
% O +
( O -
75 O -
/ O -
82 O -
) O +
of O +
breast O +
tumors O +
and O +
was O +
associated O +
with O +
lack O +
of O +
gene O +
expression O -
. O +

Hypermethylation O +
of O +
final O +
sigma O +
is O +
functionally O +
important O -
, O +
because O +
treatment O +
of O +
final O +
sigma O -
- O -
non O -
- O -
expressing O +
breast O +
cancer O +
cell O +
lines O +
with O +
the O +
drug O +
5-aza-2'-deoxycytidine B-Chemical +
resulted O +
in O +
demethylation O +
of O +
the O +
gene O +
and O +
synthesis O +
of O +
final O +
sigma O +
mRNA O -
. O +

Breast O +
cancer O +
cells O +
lacking O +
final O +
sigma O +
expression O +
showed O +
increased O +
number O +
of O +
chromosomal O +
breaks O +
and O +
gaps O +
when O +
exposed O +
to O +
gamma O -
- O -
irradiation O -
. O +

Therefore O -
, O +
it O +
is O +
possible O +
that O +
loss O +
of O +
final O +
sigma O +
expression O +
contributes O +
to O +
malignant O +
transformation O +
by O +
impairing O +
the O +
G O -
( O -
2 O -
) O +
cell O +
cycle O +
checkpoint O +
function O -
, O +
thus O +
allowing O +
an O +
accumulation O +
of O +
genetic O +
defects O -
. O +

Hypermethylation O +
and O +
loss O +
of O +
final O +
sigma O +
expression O +
are O +
the O +
most O +
consistent O +
molecular O +
alterations O +
in O +
breast O +
cancer O +
identified O +
so O +
far O -
. O +

Alpha O -
- O -
melanocyte O -
- O -
stimulating O +
hormone O +
modulates O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O +
and O +
secretion O +
of O +
interleukin-8 O +
in O +
human O +
dermal O +
fibroblasts O -
. O +

Alpha O -
- O -
melanocyte O -
- O -
stimulating O +
hormone O +
( O -
alpha O -
- O -
MSH O -
) O +
has O +
evolved O +
as O +
a O +
mediator O +
of O +
diverse O +
biological O +
activities O +
in O +
an O +
ever O -
- O -
growing O +
number O +
of O +
non O -
- O -
melanocytic O +
cell O +
types O -
. O +

One O +
mechanism O +
by O +
which O +
alpha O -
- O -
MSH O +
exerts O +
its O +
effects O +
is O +
modulation O +
of O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B. O +
These O +
two O +
transcription O +
factors O +
also O +
play O +
an O +
important O +
role O +
in O +
fibroblasts O -
, O +
in O +
extracellular O +
matrix O +
composition O -
, O +
and O +
in O +
cytokine O +
expression O -
. O +

By O +
use O +
of O +
electric O +
mobility O +
shift O +
assays O -
, O +
we O +
demonstrate O +
that O +
alpha O -
- O -
MSH O +
( O -
10 O -
( O -
-6 O -
) O +
to O +
10 O -
( O -
-14 O -
) O +
M O -
) O +
activates O +
AP-1 O +
in O +
human O +
dermal O +
fibroblasts O -
, O +
whereas O +
coincubation O +
with O +
interleukin-1 O +
beta O +
( O -
IL-1 O +
beta O -
) O +
results O +
in O +
suppression O +
of O +
its O +
activation O -
. O +

alpha O -
- O -
MSH O +
also O +
induces O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
but O +
does O +
not O +
modulate O +
DNA O +
binding O +
on O +
costimulation O +
with O +
IL-1 O +
beta O -
. O +

Since O +
AP-1 O +
and O +
NF O -
- O -
kappa O +
B O +
are O +
key O +
elements O +
in O +
controlling O +
interleukin-8 O +
( O -
IL-8 O -
) O +
transcription O -
, O +
human O +
fibroblasts O +
were O +
treated O +
with O +
alpha O -
- O -
MSH O +
and O +
IL-1 O +
beta O +
for O +
24 O +
hours O -
, O +
and O +
cytokine O +
levels O +
in O +
the O +
supernatants O +
were O +
measured O +
by O +
ELISA O -
. O +

alpha O -
- O -
MSH O +
alone O +
had O +
little O +
effect O -
, O +
whereas O +
coincubation O +
with O +
IL-1 O +
beta O +
led O +
to O +
marked O +
downregulation O +
of O +
IL-8 O +
secretion O +
( O -
at O +
most O +
288 O +
+ O -
/- O +

152 O +
ng O -
/ O -
mL O -
) O +
when O +
compared O +
to O +
treatment O +
with O +
IL-1 O +
beta O +
alone O +
( O -
919 O +
+ O -
/- O +

157 O +
ng O -
/ O -
mL O -
) O -
. O +

Our O +
results O +
indicate O +
that O +
alpha O -
- O -
MSH O +
exerts O +
modulatory O +
effects O +
on O +
the O +
activation O +
of O +
NF O -
- O -
kappa O +
B O +
and O +
AP-1 O -
, O +
and O +
that O +
it O +
can O +
regulate O +
chemokine O +
secretion O +
in O +
human O +
dermal O +
fibroblasts O -
. O +

These O +
effects O +
of O +
alpha O -
- O -
MSH O +
may O +
have O +
important O +
regulatory O +
functions O +
in O +
extracellular O +
matrix O +
composition O -
, O +
wound O +
healing O -
, O +
or O +
angiogenesis O -
. O +

Oncogenic O +
mechanisms O +
of O +
Evi-1 O +
protein O -
. O +

Although O +
Evi-1 O +
is O +
thought O +
to O +
promote O +
growth O +
or O +
block O +
differentiation O +
in O +
some O +
cell O +
types O -
, O +
its O +
biological O +
functions O +
have O +
not O +
been O +
elucidated O -
. O +

To O +
explore O +
the O +
mechanisms O +
underlying O +
Evi-1-induced O +
oncogenesis O -
, O +
we O +
investigated O +
whether O +
Evi-1 O +
affects O +
the O +
signaling O +
of O +
transforming O +
growth O +
factor O +
beta O +
( O -
TGF O -
- O -
beta O -
) O -
, O +
which O +
inhibits O +
proliferation O +
of O +
a O +
wide O +
range O +
of O +
cell O +
types O +
and O +
is O +
one O +
of O +
the O +
most O +
studied O +
growth O +
regulatory O +
factors O -
. O +

We O +
demonstrated O +
that O +
Evi-1 O +
represses O +
TGF O -
- O -
beta O +
signaling O +
and O +
antagonizes O +
its O +
growth O -
- O -
inhibitory O +
effects O -
. O +

Two O +
separate O +
regions O +
of O +
Evi-1 O +
are O +
responsible O +
for O +
this O +
repression O -
, O +
one O +
of O +
which O +
is O +
the O +
first O +
zinc O -
- O -
finger O +
domain O -
. O +

Through O +
this O +
domain O -
, O +
Evi-1 O +
physically O +
interacts O +
with O +
Smad3 O -
, O +
an O +
intracellular O +
mediator O +
of O +
TGF O -
- O -
beta O +
signaling O -
, O +
thereby O +
suppressing O +
the O +
transcriptional O +
activity O +
of O +
Smad3 O -
. O +

These O +
results O +
define O +
a O +
novel O +
function O +
of O +
Evi-1 O +
as O +
a O +
repressor O +
of O +
signaling O +
components O +
of O +
TGF O -
- O -
beta O -
. O +

We O +
also O +
demonstrated O +
that O +
Evi-1 O +
represses O +
Smad O -
- O -
induced O +
transcriptional O +
activation O +
by O +
recruiting O +
CtBP O +
as O +
a O +
corepressor O -
. O +

Evi-1 O +
associates O +
with O +
CtBP1 O +
through O +
one O +
of O +
the O +
CtBP O -
- O -
binding O +
consensus O +
motifs O +
within O +
the O +
region O +
from O +
amino O +
acid O +
544 O +
to O +
607 O -
, O +
and O +
this O +
association O +
is O +
required O +
for O +
the O +
efficient O +
inhibition O +
of O +
TGF O -
- O -
beta O +
signaling O -
. O +

A O +
specific O +
histone O +
deacetylase O +
( O -
HDAc O -
) O +
inhibitor O -
, O +
trichostatin B-Chemical +
A I-Chemical +
( O -
TSA B-Chemical -
) O -
, O +
alleviates O +
Evi-1-mediated O +
repression O +
of O +
TGF O -
- O -
beta O +
signaling O -
, O +
suggesting O +
that O +
HDAc O +
is O +
involved O +
in O +
transcriptional O +
repression O +
by O +
Evi-1 O -
. O +

This O +
identifies O +
a O +
novel O +
function O +
of O +
Evi-1 O +
as O +
a O +
member O +
of O +
corepressor O +
complexes O +
and O +
suggests O +
that O +
aberrant O +
recruitment O +
of O +
corepressors O +
is O +
one O +
of O +
the O +
mechanisms O +
involved O +
in O +
Evi-1-induced O +
leukemogenesis O -
. O +

These O +
results O +
indicate O +
that O +
specific O +
HDAc O +
inhibitors O +
may O +
be O +
useful O +
in O +
the O +
treatment O +
of O +
Evi-1-induced O +
neoplastic O +
tumors O -
, O +
including O +
myeloid O +
leukemias O -
. O +

Dominant O +
negative O +
interference O +
of O +
transcription O +
factor O +
AP-2 O +
causes O +
inhibition O +
of O +
ErbB-3 O +
expression O +
and O +
suppresses O +
malignant O +
cell O +
growth O -
. O +

ErbB-3 O +
( O -
HER3 O -
) O +
is O +
a O +
member O +
of O +
the O +
epidermal O +
growth O +
factor O +
receptor O +
family O -
. O +

Increasing O +
evidence O +
suggests O +
that O +
elevated O +
expression O +
of O +
ErbB-3 O +
is O +
important O +
for O +
malignancy O -
. O +

In O +
this O +
study O -
, O +
we O +
found O +
that O +
elevated O +
levels O +
of O +
ErbB-3 O +
expression O +
did O +
not O +
occur O +
in O +
the O +
absence O +
of O +
AP-2gamma O +
in O +
a O +
panel O +
of O +
human O +
mammary O +
epithelial O +
and O +
fibroblasts O +
cell O +
lines O -
. O +

In O +
contrast O -
, O +
there O +
was O +
no O +
association O +
between O +
the O +
expression O +
of O +
AP-2alpha O +
or O +
AP-2beta O +
and O +
the O +
level O +
of O +
ErbB-3 O -
, O +
or O +
between O +
AP-2alpha O +
and O +
AP-2gamma O +
double O +
positivity O +
and O +
ErbB-3 O +
expression O -
. O +

In O +
co O -
- O -
transfection O +
experiments O -
, O +
exogenous O +
expression O +
of O +
AP-2gamma O +
robustly O +
activated O +
ErbB-3 O +
promoter O +
activity O -
. O +

Moreover O -
, O +
expression O +
of O +
a O +
dominant O +
negative O +
AP-2 O +
protein O -
, O +
AP-2delta O +
( O -
deleted O +
residues O +
31 O -
- O -
117 O -
) O -
, O +
not O +
only O +
repressed O +
the O +
ErbB-3 O +
promoter O +
activity O +
but O +
also O +
suppressed O +
endogenous O +
ErbB-3 O +
transcription O +
in O +
the O +
ErbB-3 O +
overexpressing O +
cell O +
line O +
MRC-5VA O -
. O +

Overexpression O +
of O +
AP-2A O +
resulted O +
in O +
a O +
decreased O +
proliferation O +
rate O +
and O +
inhibitin O +
of O +
colony O +
formation O -
. O +

Taken O +
together O -
, O +
these O +
data O +
strongly O +
support O +
a O +
role O +
for O +
the O +
AP-2 O +
gene O +
family O -
, O +
in O +
particular O -
, O +
AP-2gamma O -
, O +
in O +
the O +
control O +
of O +
ErbB-3 O +
expression O -
. O +

Interference O +
with O +
the O +
function O +
of O +
transcription O +
factor O +
AP-2 O +
might O +
provide O +
a O +
potential O +
strategy O +
for O +
modulation O +
of O +
the O +
malignant O +
phenotype O -
. O +

Protein O +
expression O +
profile O +
of O +
primary O +
human O +
squamous O +
cell O +
lung O +
carcinomas O +
indicative O +
of O +
the O +
incidence O +
of O +
metastases O -
. O +

The O +
purpose O +
of O +
this O +
investigation O +
was O +
to O +
evaluate O +
firstly O +
whether O +
different O +
protein O +
expression O +
patterns O +
exist O +
in O +
primary O +
squamous O +
cell O +
lung O +
carcinomas O +
of O +
patients O +
with O +
and O +
without O +
lymph O +
node O +
involvement O +
and O +
secondly O -
, O +
whether O +
or O +
not O +
different O +
patterns O +
exist O +
in O +
tumours O +
with O +
positive O +
lymph O +
nodes O -
. O +

For O +
this O +
reason O -
, O +
formalin B-Chemical -
- O -
fixed O -
, O +
paraffin B-Chemical -
- O -
embedded O +
specimens O +
from O +
130 O +
patients O +
with O +
squamous O +
cell O +
lung O +
carcinomas O +
were O +
analyzed O +
by O +
immunohistochemistry O -
. O +

In O +
a O +
first O +
step O -
, O +
proteins O +
were O +
selected O +
which O +
showed O +
a O +
relationship O +
to O +
lymph O +
node O +
involvement O -
. O +

The O +
expression O +
of O +
JUN O -
, O +
ERBB2 O -
, O +
MYC O -
, O +
cyclin O +
D O -
, O +
PCNA O -
, O +
bFGF O -
, O +
VEGF O +
and O +
Hsp70 O +
proteins O +
revealed O +
a O +
positive O +
correlation O +
to O +
lymph O +
node O +
involvement O -
. O +

In O +
contrast O -
, O +
caspase-3 O -
, O +
Fas O +
ligand O -
, O +
Fas O -
/ O -
CD95 O -
, O +
and O +
PAI O +
showed O +
an O +
inverse O +
correlation O +
to O +
lymph O +
node O +
involvement O -
. O +

In O +
a O +
second O +
step O -
, O +
these O +
parameters O +
were O +
further O +
analyzed O +
by O +
hierarchical O +
cluster O +
analyses O -
. O +

The O +
resulting O +
clusters O +
were O +
correlated O +
to O +
patients O +
with O +
or O +
without O +
lymph O +
node O +
involvement O -
. O +

The O +
data O +
show O +
that O +
different O +
protein O +
expression O +
patterns O +
exist O +
between O +
primary O +
squamous O +
cell O +
lung O +
carcinomas O +
with O +
and O +
without O +
lymph O +
node O +
involvement O +
and O +
within O +
carcinomas O +
with O +
lymph O +
node O +
involvement O -
. O +

The O +
data O +
suggest O +
that O +
various O +
metastasis O +
profiles O +
exist O -
. O +

Adaptor O +
protein O +
Crk O +
is O +
required O +
for O +
ephrin O -
- O -
B1-induced O +
membrane O +
ruffling O +
and O +
focal O +
complex O +
assembly O +
of O +
human O +
aortic O +
endothelial O +
cells O -
. O +

Endothelial O +
cell O +
migration O +
is O +
an O +
essential O +
step O +
in O +
vasculogenesis O +
and O +
angiogenesis O -
, O +
in O +
which O +
receptor O +
tyrosine O +
kinases O +
play O +
a O +
pivotal O +
role O -
. O +

We O +
investigated O +
the O +
mechanism O +
by O +
which O +
ephrin O -
- O -
B1 O +
promotes O +
membrane O +
ruffling O +
in O +
human O +
aortic O +
endothelial O +
cells O -
, O +
because O +
membrane O +
ruffling O +
heralds O +
cell O +
body O +
migration O -
. O +

We O +
especially O +
focused O +
on O +
the O +
role O +
of O +
Crk O +
adaptor O +
protein O +
in O +
EphB O -
- O -
mediated O +
signaling O -
. O +

Using O +
DsRed B-Chemical -
- O -
tagged O +
Crk O +
and O +
a O +
fluorescent O +
time O -
- O -
lapse O +
microscope O -
, O +
we O +
showed O +
that O +
Crk O +
was O +
recruited O +
to O +
the O +
nascent O +
focal O +
complex O +
after O +
ephrin O -
- O -
B1 O +
stimulation O -
. O +

Furthermore O -
, O +
we O +
found O +
that O +
p130 O -
( O -
Cas O -
) O -
, O +
but O +
not O +
paxillin O -
, O +
recruited O +
Crk O +
to O +
the O +
nascent O +
focal O +
complex O -
. O +

The O +
necessity O +
of O +
Crk O +
in O +
ephrin O -
- O -
B1-induced O +
membrane O +
ruffling O +
was O +
shown O +
both O +
by O +
the O +
overexpression O +
of O +
dominant O +
negative O +
Crk O +
mutants O +
and O +
by O +
the O +
depletion O +
of O +
Crk O +
by O +
using O +
RNA O +
interference O -
. O +

Then O -
, O +
we O +
examined O +
the O +
role O +
of O +
two O +
major O +
downstream O +
molecules O +
of O +
Crk O -
, O +
Rac1 O +
and O +
Rap1 O -
. O +

The O +
dominant O +
negative O +
mutant O +
of O +
Rac1 O +
completely O +
inhibited O +
ephrin O -
- O -
B1-induced O +
membrane O +
ruffling O +
and O +
focal O +
complex O +
assembly O -
. O +

In O +
contrast O -
, O +
rap1GAPII O -
, O +
a O +
negative O +
regulator O +
of O +
Rap1 O -
, O +
did O +
not O +
inhibit O +
ephrin O -
- O -
B1-induced O +
membrane O +
ruffling O -
. O +

However O -
, O +
in O +
rap1GAPII O -
- O -
expressing O +
cells O -
, O +
ephrin O -
- O -
B1 O +
did O +
not O +
induce O +
membrane O +
spreading O -
, O +
probably O +
due O +
to O +
instability O +
of O +
the O +
focal O +
complex O -
. O +

These O +
results O +
indicated O +
that O +
Crk O +
plays O +
a O +
critical O +
role O +
in O +
Rac1-induced O +
membrane O +
ruffling O +
and O +
Rap1-mediated O +
nascent O +
focal O +
complex O +
stabilization O +
contributing O +
to O +
ephrin O -
- O -
B1-induced O +
human O +
aortic O +
endothelial O +
cells O +
migration O -
. O +

[ O -
Effects O +
of O +
Epstein O -
- O -
Barr O +
virus O +
latent O +
membrane O +
protein O +
1 O -
( O -
EBV O -
- O -
LMP1 O -
) O +
on O +
related O +
factors O +
of O +
metastasis O +
of O +
nasopharyngeal O +
carcinoma O +
cell O +
line O +
CNE1 O -
] O -
. O +

BACKGROUND O +
& O +
OBJECTIVE O -
: O +

It O +
has O +
been O +
proved O +
that O +
Epstein- O +
Barr O +
virus O +
( O -
EBV O -
) O +
latent O +
membrane O +
protein O +
1 O +
( O -
EBV O -
- O -
LMP1 O -
) O +
can O +
induce O +
the O +
expression O +
of O +
matrix O +
metalloproteinase-9 O +
( O -
MMP-9 O -
) O -
. O +

This O +
study O +
was O +
designed O +
to O +
investigate O +
the O +
effect O +
of O +
EBV O -
- O -
LMP1 O +
on O +
related O +
factors O +
of O +
metastasis O +
of O +
nasopharyngeal O +
carcinoma O +
cell O +
line O +
CNE1 O -
. O +

METHODS O -
: O +
Expression O +
of O +
MMP-9 O +
was O +
studied O +
in O +
human O +
NPC O +
cell O +
lines O +
cultured O +
in O +
vitro O -
: O +
CNE1 O +
( O -
well O +
differentiated O +
cell O +
line O +
of O +
NPC O -
) O +
and O +
CNE1-GL O +
( O -
CNE1 O +
cell O +
line O +
transfected O +
with O +
an O +
eukaryotic O +
LMP1-expression O +
plasmid O -
) O +
by O +
SP O +
immunohistochemistry O +
and O +
Western O +
blot O +
analysis O -
. O +

Cell O -
- O -
matrix O +
adhesion O +
assay O +
was O +
used O +
to O +
study O +
the O +
adhesive O +
ability O +
of O +
CNE1-GL O +
cells O -
. O +

The O +
effects O +
of O +
LMP1 O +
on O +
the O +
invasion O +
and O +
migration O +
of O +
CNE1 O +
cells O +
were O +
investigated O +
by O +
transwell O +
methods O -
. O +

RESULTS O -
: O +
MMP-9 O +
was O +
expressed O +
in O +
both O +
cell O +
lines O +
but O +
the O +
intensity O +
of O +
the O +
staining O +
was O +
different O -
. O +

The O +
positive O +
rates O +
of O +
expression O +
of O +
MMP-9 O +
in O +
CNE1 O +
and O +
CNE1-GL O +
cells O +
were O +
30.2 O -
% O +
and O +
98.2 O -
% O -
, O +
respectively O +
( O -
P O -
< O +
0.05 O -
) O -
. O +

The O +
increased O +
expression O +
of O +
MMP-9 O +
was O +
also O +
shown O +
in O +
CNE1-GL O +
cells O +
by O +
Western O +
blot O +
analysis O -
. O +

Cell O -
- O -
matrix O +
adhesion O +
assay O +
showed O +
that O +
the O +
adhesive O +
ability O +
of O +
CNE1-GL O +
with O +
the O +
matrix O +
( O -
mean O +
A O +
value O -
: O +
1.2508+ O -
/ O -
-0.0711 O -
) O +
was O +
higher O +
than O +
that O +
of O +
CNE1 O +
cell O +
( O -
mean O +
A O +
value O -
: O +
0.9519+ O -
/ O -
-0.068 O -
) O +
( O -
P O -
< O +
0.001 O -
) O -
. O +

Invasion O +
assay O +
and O +
migration O +
assay O +
showed O +
that O +
the O +
invasion O +
and O +
migration O +
of O +
CNE1-GL O +
cell O +
were O +
higher O +
than O +
those O +
of O +
CNE1 O +
cells O +
( O -
P O -
< O +
0.01 O -
) O -
. O +

CONCLUSION O -
: O +
The O +
transfection O +
of O +
LMP1 O +
can O +
increase O +
the O +
expression O +
of O +
MMP-9 O +
in O +
CNE1 O +
cells O -
. O +

Abilities O +
of O +
adhesion O -
, O +
migration O -
, O +
and O +
invasion O +
of O +
CNE1 O +
cell O +
were O +
induced O +
by O +
LMP1 O -
. O +

It O +
is O +
suggested O +
that O +
MMP-9 O +
may O +
have O +
a O +
role O +
in O +
the O +
LMP1-induced O +
acceleration O +
of O +
invasion O +
and O +
metastasis O +
of O +
NPC O +
cells O -
. O +

Combined O +
topical O +
fluconazole B-Chemical +
and O +
corticosteroid B-Chemical +
treatment O +
for O +
experimental O +
Candida O +
albicans O +
keratomycosis O -
. O +

PURPOSE O -
: O +
To O +
determine O +
the O +
most O +
efficient O +
time O +
point O +
and O +
concentration O +
of O +
topical O +
corticosteroids B-Chemical +
in O +
Candida O +
albicans O +
keratitis O +
treated O +
with O +
fluconazole B-Chemical -
. O +

METHODS O -
: O +
Corneas O +
of O +
105 O +
rabbits O +
were O +
infected O +
with O +
viable O +
yeast O +
cells O +
of O +
C. O +
albicans O +
( O -
2.5 O +
x O +
10 O -
( O -
5 O -
) O -
) O -
. O +

After O +
a O +
48-hour O +
incubation O +
period O -
, O +
seven O +
groups O +
of O +
animals O +
were O +
treated O +
for O +
21 O +
days O +
with O +
fluconazole B-Chemical -
, O +
with O +
group O +
I O +
acting O +
as O +
a O +
control O -
, O +
and O +
groups O +
II O +
to O +
VII O +
receiving O +
adjunct O +
therapy O +
with O +
the O +
corticosteroid B-Chemical +
prednisolone B-Chemical +
( O -
5 O +
or O +
10 O +
times O +
daily O -
; O +
3 O -
, O +
9 O -
, O +
or O +
15 O +
days O +
after O +
infection O -
) O -
. O +

The O +
degree O +
of O +
corneal O +
infiltration O -
, O +
ulceration O -
, O +
corneal O +
clouding O -
, O +
hypopyon O -
, O +
conjunctivitis O -
, O +
neovascularization O -
, O +
and O +
corneal O +
perforation O +
was O +
monitored O +
over O +
a O +
24-day O +
period O -
, O +
as O +
well O +
as O +
recultivation O +
and O +
resistance O +
to O +
fluconazole B-Chemical +
of O +
the O +
C. O +
albicans O +
pathogen O -
. O +

RESULTS O -
: O +
The O +
control O +
group O +
showed O +
the O +
highest O +
level O +
of O +
corneal O +
clouding O +
and O +
neovascularization O -
. O +

In O +
comparison O -
, O +
by O +
day O +
24 O -
, O +
the O +
majority O +
of O +
groups O +
also O +
treated O +
with O +
prednisolone B-Chemical +
displayed O +
significantly O +
less O +
corneal O +
clouding O +
and O +
neovascularization O -
. O +

An O +
immediate O +
decrease O +
in O +
corneal O +
clouding O +
was O +
observed O +
in O +
groups O +
treated O +
with O +
additional O +
low- O +
or O +
high O -
- O -
dose O +
prednisolone B-Chemical +
from O +
day O +
9 O +
after O +
inoculation O -
. O +

After O +
additional O +
prednisolone B-Chemical +
treatment O +
from O +
day O +
9 O +
or O +
15 O +
after O +
inoculation O -
, O +
no O +
significant O +
difference O +
was O +
detected O +
in O +
the O +
recultivation O +
rate O +
of O +
C. O +
albicans O +
compared O +
with O +
the O +
control O -
. O +

Early O +
administration O +
of O +
prednisolone B-Chemical +
( O -
day O +
3 O -
, O +
low O +
and O +
high O +
dose O -
) O +
resulted O +
in O +
the O +
recultivation O +
of O +
significantly O +
more O +
C. O +
albicans O -
. O +

CONCLUSIONS O -
: O +
Fluconazole B-Chemical +
plus O +
adjunct O +
high O -
- O -
dose O +
prednisolone B-Chemical +
treatment O +
was O +
most O +
effective O +
when O +
administered O +
9 O +
days O +
after O +
infection O -
. O +

The O +
delayed O +
application O +
of O +
corticosteroids B-Chemical +
after O +
treatment O +
with O +
antimycotic B-Chemical +
drugs I-Chemical +
in O +
cases O +
of O +
fungal O +
keratitis O +
is O +
therefore O +
not O +
contraindicated O +
and O +
may O +
be O +
beneficial O +
in O +
patients O -
. O +

Prognostic O +
value O +
of O +
p53 O +
protein O +
expression O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
expression O +
in O +
resected O +
squamous O +
cell O +
carcinoma O +
of O +
the O +
esophagus O -
. O +

The O +
most O +
common O +
genetic O +
alterations O +
found O +
in O +
a O +
wide O +
variety O +
of O +
cancers O +
are O +
p53 O +
tumor O +
suppressor O +
gene O +
mutations O -
. O +

p53 O +
appears O +
to O +
be O +
a O +
nuclear O +
transcription O +
factor O +
that O +
plays O +
a O +
role O +
in O +
the O +
control O +
of O +
cell O +
proliferation O -
, O +
apoptosis O -
, O +
and O +
the O +
maintenance O +
of O +
genetic O +
stability O -
. O +

Angiogenesis O +
is O +
a O +
critical O +
process O +
in O +
solid O +
tumor O +
growth O +
and O +
metastasis O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
a O +
recently O +
identified O +
growth O +
factor O +
with O +
significant O +
angiogenic O +
properties O -
, O +
may O +
be O +
a O +
major O +
tumor O +
angiogenesis O +
regulator O -
. O +

Few O +
studies O +
have O +
investigated O +
the O +
association O +
between O +
p53 O +
and O +
VEGF O +
expressions O +
and O +
prognosis O +
in O +
esophageal O +
carcinoma O -
. O +

Forty O -
- O -
seven O +
specimens O +
resected O +
from O +
patients O +
with O +
stage O +
II O +
and O +
III O +
squamous O +
cell O +
carcinoma O +
( O -
SCC O -
) O +
of O +
the O +
esophagus O +
were O +
studied O +
using O +
immunohistochemical O +
staining O -
. O +

VEGF O +
and O +
p53 O +
expressions O +
were O +
observed O +
in O +
40 O -
% O +
and O +
53 O -
% O +
of O +
the O +
tumors O -
, O +
respectively O -
. O +

The O +
p53 O +
and O +
VEGF O +
staining O +
statuses O +
were O +
coincident O +
in O +
only O +
21 O -
% O +
of O +
the O +
tumors O -
, O +
and O +
no O +
significant O +
correlation O +
was O +
found O +
between O +
p53 O +
and O +
VEGF O +
statuses O -
. O +

No O +
clinicopathologic O +
factors O +
were O +
significantly O +
correlated O +
with O +
p53 O +
or O +
VEGF O +
expression O -
. O +

No O +
significant O +
association O +
between O +
p53 O +
and O +
VEGF O +
expressions O +
and O +
poor O +
prognosis O +
was O +
found O -
. O +

In O +
conclusion O -
, O +
p53 O +
and O +
VEGF O +
were O +
not O +
correlated O +
with O +
prognosis O +
in O +
patients O +
with O +
stage O +
II O +
and O +
III O +
SCC O +
of O +
the O +
esophagus O -
. O +

Expression O +
of O +
osteoprotegerin O +
and O +
RANK O +
ligand O +
in O +
breast O +
cancer O +
bone O +
metastasis O -
. O +

Bone O +
destruction O +
is O +
primarily O +
mediated O +
by O +
osteoclastic O +
bone O +
resorption O -
, O +
and O +
cancer O +
cells O +
stimulate O +
the O +
formation O +
and O +
activation O +
of O +
osteoclasts O +
next O +
to O +
metastatic O +
foci O -
. O +

Accumulating O +
evidences O +
indicate O +
that O +
receptor O +
activator O +
of O +
NF O -
- O -
kB O +
ligand O +
( O -
RANKL O -
) O +
is O +
the O +
ultimate O +
extracellular O +
mediator O +
that O +
stimulates O +
osteoclast O +
differentiation O +
into O +
mature O +
osteoclasts O -
. O +

In O +
contrast O -
, O +
osteoprotegerin O +
( O -
OPG O -
) O +
inhibits O +
osteoclast O +
development O -
. O +

In O +
order O +
to O +
elucidate O +
a O +
mechanism O +
for O +
cancer O -
- O -
induced O +
osteoclastogenesis O -
, O +
cells O +
from O +
a O +
human O +
breast O +
cancer O +
line O -
, O +
MDA O -
- O -
MB-231 O -
, O +
were O +
directly O +
co O -
- O -
cultured O +
with O +
ST2 O -
, O +
MC3T3-E1 O -
, O +
or O +
with O +
primary O +
mouse O +
calvarial O +
cells O -
. O +

Osteoclast O -
- O -
like O +
cells O +
and O +
tartarate O +
resistant O +
acid O +
phosphatase O +
( O -
TRAP O -
) O +
activities O +
were O +
then O +
quantitated O -
. O +

We O +
examined O +
these O +
cell O +
lines O +
and O +
samples O +
from O +
breast O +
cancer O +
by O +
RT O -
- O -
PCR O +
for O +
the O +
expressions O +
of O +
OPG O +
and O +
RANKL O +
mRNA O -
. O +

Compared O +
to O +
controls O -
, O +
co O -
- O -
culture O +
of O +
MDA O -
- O -
MB-231 O +
cells O +
with O +
stromal O +
or O +
osteoblastic O +
cells O +
induced O +
an O +
increase O +
in O +
number O +
of O +
osteoclasts O +
and O +
TRAP O +
activities O -
. O +

MDA O -
- O -
MB-231 O +
cells O +
alone O +
or O +
breast O +
cancer O +
samples O +
did O +
not O +
express O +
RANKL O +
mRNA O -
. O +

However O -
, O +
co O -
- O -
culture O +
of O +
these O +
cancer O +
cells O +
with O +
stromal O +
or O +
osteoblastic O +
cells O +
induced O +
RANKL O +
mRNA O +
expression O +
and O +
decreased O +
OPG O +
mRNA O +
expression O -
. O +

These O +
experiments O +
demonstrate O +
that O +
direct O +
interactions O +
between O +
breast O +
cancer O +
and O +
stromal O +
or O +
osteoblastic O +
cells O +
induce O +
osteoclastogenesis O +
in O +
vitro O +
through O +
modulating O +
RANKL O +
expression O -
. O +

Therapeutic O +
angiogenesis O -
: O +
a O +
complex O +
problem O +
requiring O +
a O +
sophisticated O +
approach O -
. O +

Blood O +
and O +
vascular O +
disorders O +
underlie O +
a O +
plethora O +
of O +
pathologic O +
conditions O +
and O +
are O +
the O +
single O +
most O +
frequent O +
cause O +
of O +
human O +
disease O -
. O +

Ischemia O -
, O +
involving O +
restricted O +
blood O +
flow O +
to O +
tissues O +
is O +
the O +
most O +
common O +
consequence O +
of O +
vessel O +
dysfunction O +
resulting O +
in O +
the O +
disruption O +
of O +
oxygen B-Chemical +
and O +
nutrient O +
delivery O +
and O +
the O +
accumulation O +
of O +
waste O +
metabolites O -
. O +

Cells O +
can O -
not O +
survive O +
extended O +
severe O +
ischemia O +
but O +
may O +
be O +
able O +
to O +
adapt O +
to O +
a O +
moderate O +
condition O +
where O +
diffusion O +
to O +
and O +
from O +
bordering O +
nonischemic O +
regions O +
sustains O +
vital O +
functions O -
. O +

Under O +
this O +
condition O -
, O +
the O +
secondary O +
functions O +
of O +
effected O +
cells O +
are O +
likely O +
to O +
be O +
impaired O -
, O +
and O +
a O +
new O +
metabolic O +
equilibrium O +
is O +
established O -
, O +
determined O +
by O +
the O +
level O +
of O +
cross O -
- O -
diffusion O +
and O +
degree O +
of O +
hypoxia O -
. O +

In O +
tissues O +
with O +
a O +
normally O +
high O +
metabolic O +
turnover O +
such O +
as O +
skeletal O +
and O +
cardiac O +
muscle O -
, O +
even O +
mild O +
ischemia O +
causes O +
hypoxia O -
, O +
acidosis O -
, O +
and O +
depressed O +
function O +
( O -
contractility O -
) O +
and O +
eventually O +
threatens O +
myocyte O +
viability O +
and O +
organ O +
function O -
. O +

Ischemic O +
cardiac O +
muscle O +
is O +
additionally O +
vulnerable O +
because O +
reperfusion O +
is O +
essential O +
for O +
survival O +
but O +
reperfusion O +
itself O +
poses O +
additional O +
stress O +
principally O +
from O +
increased O +
production O +
of O +
free O +
radicals O +
during O +
reoxygenation O -
. O +

The O +
latter O +
effect O +
is O +
called O +
reperfusion O +
injury O +
and O +
can O +
cause O +
as O +
much O +
damage O +
as O +
the O +
ischemia O -
. O +

The O +
treatment O +
possibilities O +
for O +
ischemia O -
- O -
related O +
vascular O +
disease O +
are O +
limited O -
. O +

Lipid B-Chemical -
/ O -
cholesterol B-Chemical -
- O -
lowering O +
agents O -
, O +
diet O +
and O +
antiplatelet O +
adherence O +
( O -
aspirin B-Chemical -
) O +
therapy O +
may O +
help O +
slow O +
the O +
progression O +
of O +
vessel O +
disease O +
in O +
some O +
instances O -
; O +
but O +
surgical O +
reconstruction O +
may O +
be O +
the O +
only O +
option O +
in O +
advanced O +
stages O -
, O +
and O +
even O +
this O +
is O +
not O +
always O +
an O +
option O -
. O +

An O +
alternative O +
and O +
rather O +
obvious O +
strategy O +
to O +
treat O +
ischemia O +
is O +
to O +
activate O +
endogenous O +
angiogenic O +
or O +
arteriogenic O +
pathways O +
to O +
stimulate O +
revascularization O +
of O +
the O +
tissue O -
. O +

The O +
feasibility O +
of O +
such O +
a O +
strategy O +
has O +
now O +
been O +
established O +
through O +
the O +
results O +
of O +
studies O +
over O +
the O +
past O +
decade O -
, O +
and O +
a O +
new O +
discipline O +
called O +
therapeutic O +
angiogenesis O +
has O +
emerged O -
. O +

This O +
review O +
focuses O +
on O +
the O +
application O +
of O +
therapeutic O +
angiogenesis O +
for O +
treating O +
ischemic O +
muscle O +
disease O +
and O +
includes O +
a O +
critical O +
evaluation O +
of O +
the O +
parameters O +
and O +
limitations O +
of O +
current O +
procedures O -
. O +

The O +
development O +
of O +
this O +
technology O +
has O +
benefited O +
from O +
its O +
application O +
to O +
both O +
peripheral O +
and O +
coronary O +
artery O +
disease O +
and O +
results O +
from O +
both O +
are O +
reviewed O +
here O -
. O +

Lactoferrin O +
enhances O +
Fas O +
expression O +
and O +
apoptosis O +
in O +
the O +
colon O +
mucosa O +
of O +
azoxymethane B-Chemical -
- O -
treated O +
rats O -
. O +

Bovine O +
lactoferrin O -
, O +
a O +
multifunctional O +
glycoprotein O -
, O +
has O +
been O +
shown O +
to O +
strongly O +
inhibit O +
development O +
of O +
azoxymethane B-Chemical +
( O -
AOM B-Chemical -
) O -
-induced O +
rat O +
colon O +
tumors O -
. O +

Little O -
, O +
however O -
, O +
is O +
known O +
about O +
the O +
inhibitory O +
mechanisms O -
. O +

We O +
have O +
demonstrated O +
recently O +
that O +
lactoferrin O +
enhances O +
the O +
expression O +
of O +
a O +
member O +
of O +
the O +
tumor O +
necrosis O +
factor O +
receptor O +
family O -
, O +
Fas O -
, O +
in O +
the O +
colon O +
mucosa O +
during O +
both O +
early O +
and O +
late O +
stages O +
of O +
carcinogenesis O -
. O +

Thus O -
, O +
Fas O +
could O +
be O +
involved O +
in O +
bovine O +
lactoferrin O -
- O -
mediated O +
inhibition O +
of O +
tumor O +
development O -
. O +

To O +
investigate O +
this O +
possibility O -
, O +
we O +
studied O +
the O +
influence O +
of O +
bovine O +
lactoferrin O +
on O +
Fas O -
- O -
mediated O +
apoptosis O +
with O +
regard O +
to O +
expression O +
of O +
Fas O -
, O +
activation O +
of O +
caspase-8 O +
and O +
caspase-3 O -
, O +
and O +
DNA O +
fragmentation O +
in O +
the O +
colon O +
mucosa O +
of O +
AOM B-Chemical -
- O -
treated O +
rats O -
. O +

Western O +
blot O +
analysis O +
demonstrated O +
a O +
> O -
2.5-fold O +
increase O +
in O +
Fas O +
protein O +
expression O -
, O +
as O +
well O +
as O +
elevation O +
of O +
the O +
active O +
forms O +
of O +
both O +
caspase-8 O +
and O +
caspase-3 O -
. O +

Immunohistochemical O +
analysis O +
revealed O +
Fas O -
- O -
positive O +
cells O +
and O +
apoptotic O +
cells O +
preferentially O +
within O +
the O +
proximal O +
colon O +
region O -
, O +
clearly O +
at O +
the O +
site O +
of O +
bovine O +
lactoferrin O -
- O -
mediated O +
tumor O +
inhibition O -
. O +

These O +
results O +
suggest O +
that O +
apoptosis O +
caused O +
by O +
elevated O +
expression O +
of O +
Fas O +
is O +
involved O +
in O +
chemoprevention O +
by O +
lactoferrin O +
of O +
colon O +
carcinogenesis O -
. O +

Differential O +
proteomic O +
analysis O +
of O +
human O +
hepatocellular O +
carcinoma O +
cell O +
line O +
metastasis O -
- O -
associated O +
proteins O -
. O +

PURPOSE O -
: O +
The O +
comparative O +
study O +
of O +
differentially O +
expression O +
of O +
protein O +
profiles O +
of O +
hepatocellular O +
carcinoma O +
cell O +
lines O +
with O +
various O +
metastasic O +
potential O +
and O +
screening O +
key O +
molecules O +
related O +
to O +
hepatocellular O +
carcinoma O +
metastasis O +
and O +
recurrence O -
. O +

METHODS O -
: O +
Using O +
two O -
- O -
dimensional O +
electrophoresis O +
and O +
liquid O +
chromatography O -
- O -
electrospray O +
ionization O -
- O -
tandem O +
mass O +
spectrometry O +
( O -
LC O -
- O -
ESI O -
- O -
MS O -
/ O -
MS O -
) O -
, O +
we O +
analyzed O +
differentially O +
displayed O +
proteomics O +
of O +
human O +
hepatocellular O +
carcinoma O +
cell O +
lines O +
Hep3B O -
, O +
MHCC97L O -
, O +
MHCC97H O +
with O +
different O +
metastasic O +
potential O -
. O +

RESULTS O -
: O +
Approximate O +
1,000 O +
protein O +
spots O +
were O +
detected O +
on O +
silver B-Chemical -
- O -
stained O +
gel O +
by O +
ImageMaster O +
( O -
977+ O -
/ O -
-113 O +
spots O +
in O +
Hep3B O -
, O +
1092+ O -
/ O -
-40 O +
in O +
MHCC97L O -
, O +
and O +
889+ O -
/ O -
-14 O +
in O +
MHCC97H O -
) O -
. O +

Fifty O +
distinct O +
different O +
protein O +
spots O +
were O +
analyzed O +
with O +
online O +
LC O -
- O -
ESI O -
- O -
MS O -
/ O -
MS O -
. O +

Only O +
26 O +
protein O +
spots O +
had O +
a O +
positive O +
result O -
, O +
including O +
annexin1 O -
, O +
S100A4 O -
, O +
and O +
so O +
on O -
. O +

In O +
comparison O +
with O +
nonmetastasis O +
Hep3B O +
cell O +
lines O -
, O +
there O +
were O +
16 O +
proteins O +
overexpressed O +
in O +
MHCC97H O +
and O +
MHCC97L O -
, O +
10 O +
proteins O +
underexpressed O +
in O +
MHCC97H O +
and O +
MHCC97L O -
. O +

Applying O +
cell O +
immunohistochemistry O +
and O +
RT O -
- O -
PCR O -
, O +
we O +
further O +
validated O +
two O +
interesting O +
and O +
different O +
proteins O -
, O +
annexin1 O +
and O +
S100A4 O -
. O +

CONCLUSION O -
: O +
The O +
protein O +
profile O +
of O +
metastatic O +
hepatocellular O +
carcinoma O +
cell O +
lines O +
displayed O +
obvious O +
differences O +
compared O +
with O +
non O -
- O -
metastatic O +
liver O +
cancer O +
cell O +
lines O -
. O +

The O +
results O +
imply O +
that O +
various O +
different O +
proteins O +
may O +
lead O +
to O +
HCC O +
metastasis O +
together O -
. O +

VEGF O -
- O -
targeted O +
therapy O -
: O +
therapeutic O +
potential O +
and O +
recent O +
advances O -
. O +

After O +
over O +
30 O +
years O +
of O +
theorizing O -
, O +
the O +
use O +
of O +
angiogenesis O +
inhibitors O +
as O +
anticancer O +
therapy O +
has O +
finally O +
moved O +
from O +
the O +
realm O +
of O +
research O +
to O +
reality O -
. O +

Normal O +
adult O +
vasculature O +
is O +
generally O +
quiescent O +
in O +
nature O -
, O +
with O +
endothelial O +
cells O +
dividing O +
approximately O +
every O +
10 O +
years O -
. O +

In O +
contrast O -
, O +
the O +
growth O +
of O +
tumors O +
requires O +
constant O +
vascular O +
growth O +
and O +
remodeling O +
in O +
order O +
for O +
solid O +
tumors O +
to O +
grow O +
beyond O +
1 O -
- O -
2 O +
mm O -
( O -
3 O -
) O +
in O +
size O -
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
and O +
its O +
receptors O +
are O +
key O +
regulators O +
of O +
the O +
process O +
of O +
angiogenesis O -
, O +
which O +
makes O +
them O +
attractive O +
therapeutic O +
targets O -
. O +

A O +
multitude O +
of O +
VEGF O -
- O -
targeted O +
inhibitory O +
agents O +
are O +
currently O +
being O +
investigated O +
for O +
the O +
treatment O +
of O +
cancer O -
. O +

This O +
review O +
article O +
focuses O +
on O +
recent O +
developments O +
in O +
the O +
use O +
of O +
angiogenesis O +
inhibitors O +
for O +
the O +
treatment O +
of O +
breast O -
, O +
lung O -
, O +
and O +
colorectal O +
cancers O -
. O +

MDM2 O +
as O +
a O +
predictor O +
of O +
prostate O +
carcinoma O +
outcome O -
: O +
an O +
analysis O +
of O +
Radiation O +
Therapy O +
Oncology O +
Group O +
Protocol O +
8610 O -
. O +

BACKGROUND O -
: O +
The O +
MDM2 O +
oncoprotein O +
promotes O +
p53 O +
degradation O +
via O +
ubiquitin O -
, O +
establishing O +
negative O +
feedback O +
control O +
of O +
p53 O +
and O +
consequently O +
affecting O +
cell O +
cycle O +
arrest O +
and O +
apoptosis O -
. O +

The O +
authors O +
evaluated O +
the O +
association O +
between O +
MDM2 O +
expression O +
and O +
local O +
failure O -
, O +
distant O +
metastasis O +
( O -
DM O -
) O -
, O +
cause O -
- O -
specific O +
mortality O -
, O +
and O +
overall O +
mortality O +
in O +
men O +
treated O +
in O +
Radiation O +
Therapy O +
Oncology O +
Group O +
8610 O +
with O +
radiotherapy O -
, O +
with O +
or O +
without O +
androgen B-Chemical +
deprivation O -
. O +

METHODS O -
: O +
Of O +
the O +
456 O +
eligible O +
and O +
analyzable O +
patients O +
( O -
parent O +
cohort O -
) O -
, O +
adequate O +
archival O +
diagnostic O +
tissue O +
specimens O +
from O +
108 O +
patients O +
were O +
available O +
for O +
MDM2 O +
analysis O +
( O -
MDM2 O +
cohort O -
) O -
. O +

Cox O +
proportional O +
hazards O +
multivariate O +
analysis O +
( O -
MVA O -
) O +
was O +
used O +
to O +
determine O +
the O +
relation O +
of O +
MDM2 O +
to O +
the O +
endpoints O -
. O +

MDM2 O +
overexpression O +
was O +
manually O +
classified O +
as O +
> O +
5 O -
% O +
nuclear O +
staining O -
. O +

An O +
image O +
analysis O +
system O +
was O +
also O +
used O +
to O +
quantify O +
the O +
proportion O +
of O +
tumor O +
nuclei O +
with O +
MDM2 O +
staining O +
( O -
ACIS O +
index O -
) O +
and O +
staining O +
intensity O -
. O +

RESULTS O -
: O +
Overexpression O +
of O +
MDM2 O +
by O +
manual O +
counts O +
was O +
seen O +
in O +
44 O -
% O +
( O -
n O +
= O +
47 O -
) O +
of O +
the O +
patients O -
. O +

In O +
the O +
manual O +
count O +
analysis O -
, O +
there O +
was O +
no O +
significant O +
relation O +
between O +
MDM2 O +
overexpression O +
and O +
outcome O -
. O +

The O +
ACIS O +
index O -
, O +
using O +
a O +
cutoff O +
point O +
defined O +
by O +
the O +
median O +
value O -
, O +
< O +
or O +
= O +
3 O -
% O +
versus O +
> O +
3 O -
% O -
, O +
was O +
related O +
to O +
5-year O +
DM O +
rates O +
in O +
univariate O +
analyses O +
( O -
32.6 O -
% O +
vs. O +
45.8 O -
% O -
; O +
P O +
= O +
0.057 O -
) O +
and O +
MVA O +
( O -
P O +
= O +
0.06 O -
) O -
. O +

The O +
intensity O +
of O +
MDM2 O +
staining O +
was O +
not O +
significant O -
. O +

CONCLUSIONS O -
: O +
MDM2 O +
expression O +
quantified O +
by O +
image O +
analysis O +
was O +
weakly O +
associated O +
with O +
DM O -
. O +

The O +
cohort O +
examined O +
was O +
relatively O +
small O +
and O +
with O +
larger O +
patient O +
numbers O -
, O +
MDM2 O +
overexpression O +
may O +
emerge O +
as O +
a O +
more O +
significant O +
covariate O -
. O +

Bovine O +
papillomavirus O +
E7 O +
transformation O +
function O +
correlates O +
with O +
cellular O +
p600 O +
protein O +
binding O -
. O +

The O +
E7 O +
oncoprotein O +
of O +
bovine O +
papillomavirus O +
type O +
1 O +
( O -
BPV-1 O -
) O +
is O +
required O +
for O +
the O +
full O +
transformation O +
activity O +
of O +
the O +
virus O -
. O +

However O -
, O +
the O +
mechanism O +
by O +
which O +
E7 O +
contributes O +
to O +
cellular O +
transformation O +
is O +
unknown O -
. O +

To O +
address O +
this O +
question O -
, O +
we O +
used O +
the O +
proteomic O +
approach O +
of O +
tandem O +
affinity O +
purification O +
to O +
identify O +
cellular O +
proteins O +
that O +
are O +
in O +
complex O +
with O +
E7 O -
, O +
and O +
identified O +
the O +
600-kDa O +
protein O -
, O +
p600 O -
, O +
as O +
a O +
binding O +
partner O +
of O +
E7 O -
. O +

The O +
ability O +
of O +
E7 O +
to O +
complex O +
with O +
p600 O +
correlated O +
with O +
its O +
ability O +
to O +
enhance O +
anchorage O +
independence O +
of O +
BPV-1 O +
E6-expressing O +
cells O -
. O +

Furthermore O -
, O +
E7 O +
mutant O +
proteins O +
impaired O +
in O +
their O +
ability O +
to O +
bind O +
p600 O +
were O +
transformation O +
defective O -
. O +

Additionally O -
, O +
knockdown O +
of O +
p600 O +
reduced O +
transformation O +
of O +
cells O +
expressing O +
both O +
BPV-1 O +
E6 O +
and O +
E7 O -
, O +
as O +
well O +
as O +
E6 O +
alone O -
, O +
suggesting O +
that O +
the O +
ability O +
of O +
E7 O +
to O +
transformed O +
cells O +
is O +
mediated O -
, O +
at O +
least O +
in O +
part O -
, O +
through O +
its O +
ability O +
to O +
bind O +
p600 O -
. O +

These O +
data O +
complement O +
work O +
that O +
shows O +
that O +
HPV16 O +
E7 O +
also O +
interacts O +
with O +
p600 O -
, O +
and O +
that O +
this O +
interaction O +
correlates O +
with O +
the O +
ability O +
of O +
HPV16 O +
E7 O +
to O +
transform O +
cells O -
. O +

These O +
studies O +
thus O +
identify O +
p600 O +
as O +
a O +
shared O +
target O +
of O +
the O +
E7 O +
proteins O +
of O +
multiple O +
papillomaviruses O -
. O +

The O +
threshold O +
level O +
of O +
adenomatous O +
polyposis O +
coli O +
protein O +
for O +
mouse O +
intestinal O +
tumorigenesis O -
. O +

The O +
adenomatous O +
polyposis O +
coli O +
( O -
APC O -
) O +
gene O -
, O +
whose O +
mutations O +
are O +
responsible O +
for O +
familial O +
adenomatous O +
polyposis O -
, O +
is O +
a O +
major O +
negative O +
controller O +
of O +
the O +
Wnt O -
/ O -
beta O -
- O -
catenin O +
pathway O -
. O +

To O +
investigate O +
the O +
dose O -
- O -
dependent O +
effects O +
of O +
APC O +
protein O +
in O +
suppressing O +
intestinal O +
tumorigenesis O -
, O +
we O +
constructed O +
mutant O +
mice O +
carrying O +
hypomorphic O +
Apc O +
alleles O +
Apc O -
( O -
neoR O -
) O +
and O +
Apc O -
( O -
neoF O -
) O +
whose O +
expression O +
levels O +
were O +
reduced O +
to O +
20 O -
% O +
and O +
10 O -
% O +
of O +
the O +
wild O +
type O -
, O +
respectively O -
. O +

Although O +
both O +
hypomorphic O +
heterozygotes O +
developed O +
intestinal O +
polyps O -
, O +
tumor O +
multiplicities O +
were O +
much O +
lower O +
than O +
that O +
in O +
Apc O -
( O -
Delta716 O -
) O +
mice O -
, O +
heterozygotes O +
of O +
an O +
Apc O +
null O +
allele O -
. O +

Like O +
in O +
Apc O -
( O -
Delta716 O -
) O +
mice O -
, O +
loss O +
of O +
the O +
wild O -
- O -
type O +
Apc O +
allele O +
was O +
confirmed O +
for O +
all O +
polyps O +
examined O +
in O +
the O +
Apc O -
( O -
neoR O -
) O +
and O +
Apc O -
( O -
neoF O -
) O +
mice O -
. O +

In O +
the O +
embryonic O +
stem O +
cells O +
homozygous O +
for O +
these O +
hypomorphic O +
Apc O +
alleles O -
, O +
the O +
level O +
of O +
the O +
APC O +
protein O +
was O +
inversely O +
correlated O +
with O +
both O +
the O +
beta O -
- O -
catenin O +
accumulation O +
and O +
beta O -
- O -
catenin O -
/ O -
T O -
- O -
cell O +
factor O +
transcriptional O +
activity O -
. O +

These O +
results O +
suggest O +
that O +
the O +
reduced O +
APC O +
protein O +
level O +
increases O +
intestinal O +
polyp O +
multiplicity O +
through O +
quantitative O +
stimulation O +
of O +
the O +
beta O -
- O -
catenin O -
/ O -
T O -
- O -
cell O +
factor O +
transcription O -
. O +

We O +
further O +
estimated O +
the O +
threshold O +
of O +
APC O +
protein O +
level O +
that O +
forms O +
one O +
polyp O +
per O +
mouse O +
as O +
approximately O +
15 O -
% O +
of O +
the O +
wild O +
type O -
. O +

These O +
results O +
also O +
suggest O +
therapeutic O +
implications O +
concerning O +
Wnt O +
signaling O +
inhibitors O -
. O +

Normal O +
and O +
transforming O +
functions O +
of O +
RUNX1 O -
: O +
a O +
perspective O -
. O +

Converging O +
studies O +
from O +
many O +
investigators O +
indicate O +
that O +
RUNX1 O +
has O +
a O +
critical O +
role O +
in O +
the O +
correct O +
maintenance O +
of O +
essential O +
cellular O +
functions O +
during O +
embryonic O +
development O +
and O +
after O +
birth O -
. O +

The O +
discovery O +
that O +
this O +
gene O +
is O +
also O +
frequently O +
mutated O +
in O +
human O +
leukemia O +
has O +
increased O +
the O +
interest O +
in O +
the O +
role O +
that O +
RUNX1 O +
plays O +
in O +
both O +
normal O +
and O +
transforming O +
pathways O -
. O +

Here O -
, O +
we O +
provide O +
an O +
overview O +
of O +
the O +
many O +
roles O +
of O +
RUNX1 O +
in O +
hematopoietic O +
self O -
- O -
renewal O +
and O +
differentiation O +
and O +
summarize O +
the O +
information O +
that O +
is O +
currently O +
available O +
on O +
the O +
many O +
mechanisms O +
of O +
RUNX1 O +
deregulation O +
in O +
human O +
leukemia O -
. O +

Regulation O +
of O +
tumor O +
angiogenesis O +
by O +
thrombospondin-1 O -
. O +

Angiogenesis O +
plays O +
a O +
critical O +
role O +
in O +
the O +
growth O +
and O +
metastasis O +
of O +
tumors O -
. O +

Thrombospondin-1 O +
( O -
TSP-1 O -
) O +
is O +
a O +
potent O +
angiogenesis O +
inhibitor O -
, O +
and O +
down O -
- O -
regulation O +
of O +
TSP-1 O +
has O +
been O +
suggested O +
to O +
alter O +
tumor O +
growth O +
by O +
modulating O +
angiogenesis O +
in O +
a O +
variety O +
of O +
tumor O +
types O -
. O +

Expression O +
of O +
TSP-1 O +
is O +
up O -
- O -
regulated O +
by O +
the O +
tumor O +
suppressor O +
gene O -
, O +
p53 O -
, O +
and O +
down O -
- O -
regulated O +
by O +
oncogenes O +
such O +
as O +
Myc O +
and O +
Ras O -
. O +

TSP-1 O +
inhibits O +
angiogenesis O +
by O +
inhibiting O +
endothelial O +
cell O +
migration O +
and O +
proliferation O +
and O +
by O +
inducing O +
apoptosis O -
. O +

In O +
addition O -
, O +
activation O +
of O +
transforming O +
growth O +
factor O +
beta O +
( O -
TGF O -
- O -
beta O -
) O +
by O +
TSP-1 O +
plays O +
a O +
crucial O +
role O +
in O +
the O +
regulation O +
of O +
tumor O +
progression O -
. O +

An O +
understanding O +
of O +
the O +
molecular O +
basis O +
of O +
TSP-1-mediated O +
inhibition O +
of O +
angiogenesis O +
and O +
tumor O +
progression O +
will O +
aid O +
in O +
the O +
development O +
of O +
novel O +
therapeutics O +
for O +
the O +
treatment O +
of O +
cancer O -
. O +

Hepatitis O +
B O +
virus O +
integration O +
event O +
in O +
human O +
chromosome O +
17p O +
near O +
the O +
p53 O +
gene O +
identifies O +
the O +
region O +
of O +
the O +
chromosome O +
commonly O +
deleted O +
in O +
virus O -
- O -
positive O +
hepatocellular O +
carcinomas O -
. O +

The O +
development O +
of O +
hepatocellular O +
carcinoma O +
( O -
HCC O -
) O +
presumably O +
occurs O +
in O +
multiple O +
steps O +
and O +
is O +
influenced O +
by O +
numerous O +
factors O -
. O +

Hepatitis O +
B O +
virus O +
( O -
HBV O -
) O +
is O +
strongly O +
associated O +
with O +
the O +
development O +
of O +
HCC O +
in O +
people O +
chronically O +
infected O +
with O +
the O +
virus O -
, O +
but O +
the O +
mechanism O +
of O +
viral O +
involvement O +
remains O +
unclear O -
. O +

One O +
possibility O +
is O +
that O +
the O +
gross O +
chromosomal O +
alterations O +
frequently O +
observed O +
in O +
HCC O +
DNA O +
at O +
the O +
site O +
of O +
HBV O +
integration O +
may O +
alter O +
the O +
expression O +
of O +
important O +
nearby O +
cellular O +
genes O -
. O +

We O +
previously O +
reported O +
the O +
cloning O +
and O +
characterization O +
of O +
a O +
HBV O +
insert O +
from O +
a O +
Chinese O +
HCC O -
. O +

The O +
viral O +
insert O +
mapped O +
to O +
chromosome O +
17p11.2 O -
- O -
12 O -
, O +
and O +
cellular O +
sequences O +
were O +
duplicated O +
at O +
the O +
site O +
of O +
viral O +
integration O -
. O +

In O +
the O +
present O +
study O +
a O +
DNA O +
probe O +
derived O +
from O +
cellular O +
DNA O +
sequences O +
adjacent O +
to O +
the O +
previously O +
characterized O +
HBV O +
insert O +
was O +
used O +
to O +
analyze O +
a O +
set O +
of O +
19 O +
matched O +
normal O +
liver O +
and O +
HBV O -
- O -
positive O +
hepatoma O +
samples O +
obtained O +
from O +
the O +
same O +
region O +
of O +
China O -
, O +
near O +
Shanghai O -
. O +

Tumor O -
- O -
specific O +
DNA O +
changes O +
were O +
detected O +
in O +
two O +
additional O +
HCCs O -
, O +
suggesting O +
that O +
the O +
small O +
region O +
of O +
chromosome O +
17p O +
defined O +
by O +
the O +
flanking O +
cell O +
DNA O +
probe O +
is O +
commonly O +
altered O +
in O +
hepatomas O -
. O +

Restriction O +
fragment O +
length O +
polymorphism O +
studies O +
demonstrated O +
that O +
the O +
loss O +
of O +
one O +
copy O +
of O +
portions O +
of O +
chromosome O +
17 O +
occurred O +
in O +
10 O +
( O -
53 O -
% O -
) O +
of O +
the O +
19 O +
patients O -
. O +

The O +
loss O +
of O +
one O +
allele O +
of O +
the O +
p53 O +
gene O +
( O -
located O +
on O +
chromosome O +
17p13 O -
) O +
occurred O +
in O +
at O +
least O +
6 O +
( O -
60 O -
% O -
) O +
of O +
the O +
10 O +
patients O +
who O +
were O +
heterozygous O +
at O +
the O +
p53 O +
locus O -
. O +

As O +
the O +
p53 O +
gene O +
is O +
known O +
to O +
possess O +
tumor O +
suppressor O +
activity O -
, O +
the O +
functional O +
loss O +
of O +
this O +
gene O +
may O +
be O +
a O +
significant O +
step O +
in O +
the O +
development O +
of O +
a O +
subset O +
of O +
HCCs O -
. O +

High O +
levels O +
of O +
allele O +
loss O +
also O +
were O +
detected O +
for O +
chromosomes O +
8q O +
( O -
4 O +
of O +
9 O -
; O +
44 O -
% O -
) O +
and O +
16p O +
( O -
5 O +
of O +
6 O -
; O +
83 O -
% O -
) O +
and O +
may O +
indicate O +
the O +
presence O +
of O +
additional O +
cellular O +
genes O +
whose O +
functional O +
loss O +
is O +
important O +
in O +
the O +
development O +
of O +
HCCs O -
. O +

Recombinant O +
human O +
prothrombin O +
kringle-2 O +
inhibits O +
B16F10 O +
melanoma O +
metastasis O +
through O +
inhibition O +
of O +
neovascularization O +
and O +
reduction O +
of O +
matrix O +
metalloproteinase O +
expression O -
. O +

Angiogenesis O -
, O +
a O +
multi O -
- O -
step O +
process O +
which O +
involves O +
endothelial O +
cell O +
proliferation O -
, O +
adhesion O -
, O +
migration O -
, O +
and O +
basement O +
membrane O +
( O -
BM O -
) O +
degradation O -
, O +
is O +
essential O +
for O +
tumor O +
metastasis O -
. O +

Here O +
we O +
show O +
that O +
recombinant O +
human O +
prothrombin O +
kringle-2 O +
( O -
rk-2 O -
) O +
inhibited O +
bovine O +
capillary O +
endothelial O +
cell O +
migration O +
with O +
an O +
IC O -
( O -
50 O -
) O +
( O -
concentration O +
for O +
half O +
maximal O +
inhibition O -
) O +
of O +
38 O +
nM O +
and O +
inhibited O +
adhesion O +
to O +
extracellular O +
matrix O +
( O -
ECM O -
) O +
proteins O -
. O +

Because O +
tumor O +
metastasis O +
requires O +
angiogenesis O -
, O +
we O +
examined O +
whether O +
rk-2 O +
could O +
inhibit O +
metastases O +
induced O +
by O +
injection O +
of O +
B16F10 O +
melanoma O +
cells O +
into O +
mice O -
. O +

The O +
results O +
revealed O +
that O +
the O +
metastatic O +
tumors O +
in O +
mouse O +
lung O +
were O +
markedly O +
decreased O +
in O +
a O +
dose O -
- O -
dependent O +
manner O +
and O +
acute O +
lung O +
injury O +
induced O +
by O +
B16F10 O +
melanoma O +
metastasis O +
was O +
diminished O +
by O +
systemic O +
rk-2 O +
treatment O -
. O +

In O +
immunohistochemical O +
analysis O -
, O +
rk-2 O +
reduced O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O -
, O +
which O +
is O +
a O +
potent O +
angiogenic O +
activator O +
and O +
neovascularization O +
in O +
the O +
mouse O +
lung O -
. O +

Also O -
, O +
rk-2 O +
diminished O +
the O +
expression O +
of O +
matrix O +
metalloproteinase-2 O +
and O +
-9 O +
in O +
the O +
mouse O +
lung O +
which O +
induces O +
tumor O +
metastasis O +
and O +
angiogenesis O -
. O +

These O +
data O +
suggest O +
that O +
inhibition O +
of O +
B16F10 O +
melanoma O +
metastasis O +
by O +
rk-2 O +
was O +
caused O +
by O +
inhibition O +
of O +
neovascularization O +
and O +
reduction O +
of O +
matrix O +
metalloproteinase O +
expression O -
. O +

Activation O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
through O +
reactive B-Chemical +
oxygen I-Chemical +
species I-Chemical +
mediates O +
20-hydroxyeicosatetraenoic B-Chemical +
acid I-Chemical -
- O -
induced O +
endothelial O +
cell O +
proliferation O -
. O +

20-Hydroxyeicosatetraenoic B-Chemical +
acid I-Chemical +
( O -
20-HETE B-Chemical -
) O +
is O +
formed O +
by O +
the O +
omega O -
- O -
hydroxylation O +
of O +
arachidonic B-Chemical +
acid I-Chemical +
by O +
cytochrome O +
P450 O +
4A O +
and O +
4F O +
enzymes O -
, O +
and O +
it O +
induces O +
angiogenic O +
responses O +
in O +
vivo O -
. O +

To O +
test O +
the O +
hypothesis O +
that O +
20-HETE B-Chemical +
increases O +
endothelial O +
cell O +
( O -
EC O -
) O +
proliferation O +
via O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O -
, O +
we O +
studied O +
the O +
effects O +
of O +
WIT003 B-Chemical +
[ O -
20-hydroxyeicosa-5 B-Chemical -
( I-Chemical -
Z I-Chemical -
) I-Chemical -
,14 I-Chemical -
( I-Chemical -
Z I-Chemical -
) I-Chemical -
-dienoic I-Chemical +
acid I-Chemical -
] O -
, O +
a O +
20-HETE B-Chemical +
analog O +
on O +
human O +
macrovascular O +
or O +
microvascular O +
EC O -
. O +

WIT003 B-Chemical -
, O +
as O +
well O +
as O +
pure O +
20-HETE B-Chemical -
, O +
stimulated O +
EC O +
proliferation O +
by O +
approximately O +
40 O -
% O -
. O +

These O +
proliferative O +
effects O +
were O +
accompanied O +
by O +
increased O +
VEGF O +
expression O +
and O +
release O +
that O +
were O +
observed O +
as O +
early O +
as O +
4 O +
h O +
after O +
20-HETE B-Chemical +
agonist O +
addition O -
. O +

This O +
was O +
accompanied O +
by O +
increased O +
phosphorylation O +
of O +
the O +
VEGF O +
receptor O +
2 O -
. O +

The O +
proliferative O +
effects O +
of O +
20-HETE B-Chemical +
were O +
markedly O +
inhibited O +
by O +
a O +
VEGF O -
- O -
neutralizing O +
antibody O -
. O +

Polyethylene B-Chemical +
glycol I-Chemical -
- I-Chemical -
superoxide I-Chemical +
dismutase I-Chemical +
( O -
PEG B-Chemical -
- I-Chemical -
SOD I-Chemical -
) O +
markedly O +
inhibited O +
both O +
the O +
increases O +
in O +
VEGF O +
expression O +
and O +
the O +
proliferative O +
effects O +
of O +
20-HETE B-Chemical -
. O +

In O +
contrast O -
, O +
administration O +
of O +
the O +
NAD O -
( O -
P O -
) O -
H O +
oxidase O +
inhibitor O +
apocynin B-Chemical +
had O +
no O +
effect O +
to O +
the O +
proliferative O +
response O +
to O +
20-HETE B-Chemical -
. O +

The O +
20-HETE B-Chemical +
agonist O +
markedly O +
increased O +
superoxide B-Chemical +
formation O +
as O +
reflected O +
by O +
an O +
increase O +
in O +
dihydroethidium B-Chemical +
staining O +
of O +
EC O -
, O +
and O +
this O +
increase O +
was O +
inhibited O +
by O +
PEG B-Chemical -
- I-Chemical -
SOD I-Chemical +
but O +
not O +
by O +
apocynin B-Chemical -
. O +

20-HETE B-Chemical +
also O +
increased O +
the O +
phosphorylation O +
of O +
p42 O -
/ O -
p44 O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
in O +
EC O -
, O +
whereas O +
an O +
inhibitor O +
of O +
MAPK O +
[ O -
U0126 B-Chemical -
, O +
1,4-diamino-2,3-dicyano-1,4-bis B-Chemical -
( I-Chemical -
2-aminophenylthio I-Chemical -
) I-Chemical -
butadiene I-Chemical -
] O +
suppressed O +
the O +
proliferative O +
and O +
the O +
VEGF O +
changes O +
but O +
not O +
the O +
pro O -
- O -
oxidant O +
effects O +
of O +
20-HETE B-Chemical -
. O +

These O +
data O +
suggest O +
that O +
20-HETE B-Chemical +
stimulates O +
superoxide B-Chemical +
formation O +
by O +
pathways O +
other O +
than O +
apocynin B-Chemical -
- O -
sensitive O +
NAD O -
( O -
P O -
) O -
H O +
oxidase O -
, O +
thereby O +
activating O +
MAPK O +
and O +
then O +
enhancing O +
VEGF O +
synthesis O +
that O +
drives O +
EC O +
proliferation O -
. O +

Thus O -
, O +
20-HETE B-Chemical +
may O +
be O +
involved O +
in O +
the O +
regulation O +
of O +
EC O +
functions O -
, O +
such O +
as O +
angiogenesis O -
. O +

Pro O -
/ O -
antioxidant O +
status O +
and O +
AP-1 O +
transcription O +
factor O +
in O +
murine O +
skin O +
following O +
topical O +
exposure O +
to O +
cumene B-Chemical +
hydroperoxide I-Chemical -
. O +

Organic B-Chemical +
peroxides I-Chemical -
, O +
widely O +
used O +
in O +
the O +
chemical O +
and O +
pharmaceutical O +
industries O -
, O +
can O +
act O +
as O +
skin O +
tumor O +
promoters O +
and O +
cause O +
epidermal O +
hyperplasia O -
. O +

They O +
are O +
also O +
known O +
to O +
trigger O +
free B-Chemical +
radical I-Chemical +
generation O -
. O +

The O +
present O +
study O +
evaluated O +
the O +
effect O +
of O +
cumene B-Chemical +
hydroperoxide I-Chemical +
( O -
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical -
) O +
on O +
the O +
induction O +
of O +
activator O +
protein-1 O +
( O -
AP-1 O -
) O -
, O +
which O +
is O +
linked O +
to O +
the O +
expression O +
of O +
genes O +
regulating O +
cell O +
proliferation O -
, O +
growth O +
and O +
transformation O -
. O +

Previously O -
, O +
we O +
reported O +
that O +
topical O +
exposure O +
to O +
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical +
caused O +
formation O +
of O +
free B-Chemical +
radicals I-Chemical +
and O +
oxidative O +
stress O +
in O +
the O +
skin O +
of O +
vitamin B-Chemical +
E I-Chemical -
- O -
deficient O +
mice O -
. O +

The O +
present O +
study O +
used O +
JB6 O +
P+ O +
mouse O +
epidermal O +
cells O +
and O +
AP-1-luciferase O +
reporter O +
transgenic O +
mice O +
to O +
identify O +
whether O +
exposure O +
to O +
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical +
caused O +
activation O +
of O +
AP-1 O -
, O +
oxidative O +
stress O -
, O +
depletion O +
of O +
antioxidants O +
and O +
tumor O +
formation O +
during O +
two O -
- O -
stage O +
carcinogenesis O -
. O +

In O +
vitro O +
studies O +
found O +
that O +
exposure O +
to O +
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical +
reduced O +
the O +
level O +
of O +
glutathione B-Chemical +
( O -
GSH B-Chemical -
) O +
in O +
mouse O +
epidermal O +
cells O +
( O -
JB6 O +
P+ O -
) O +
and O +
caused O +
the O +
induction O +
of O +
AP-1 O -
. O +

Mice O +
primed O +
with O +
dimethyl B-Chemical -
- I-Chemical -
benz I-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
anthracene I-Chemical +
( O -
DMBA B-Chemical -
) O +
were O +
topically O +
exposed O +
to O +
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical +
( O -
82.6 O +
micromol O -
) O +
or O +
the O +
positive O +
control O -
, O +
12-O B-Chemical -
- I-Chemical -
tetradecanoylphorbol-13-acetate I-Chemical +
( O -
TPA B-Chemical -
, O +
17 O +
nmol O -
) O -
, O +
twice O +
weekly O +
for O +
29 O +
weeks O -
. O +

Activation O +
of O +
AP-1 O +
in O +
skin O +
was O +
detected O +
as O +
early O +
as O +
2 O +
weeks O +
following O +
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical +
or O +
TPA B-Chemical +
exposure O -
. O +

No O +
AP-1 O +
expression O +
was O +
found O +
19 O +
weeks O +
after O +
initiation O -
. O +

Papilloma O +
formation O +
was O +
observed O +
in O +
both O +
the O +
DMBA B-Chemical -
- O -
TPA- B-Chemical +
and O +
DMBA B-Chemical -
- O -
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical -
- O -
exposed O +
animals O -
, O +
whereas O +
skin O +
carcinomas O +
were O +
found O +
only O +
in O +
the O +
DMBA B-Chemical -
- O -
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical -
- O -
treated O +
mice O -
. O +

A O +
greater O +
accumulation O +
of O +
peroxidative O +
products O +
( O -
thiobarbituric B-Chemical +
acid I-Chemical -
- O -
reactive O +
substances O -
) O -
, O +
inflammation O +
and O +
decreased O +
levels O +
of O +
GSH B-Chemical +
and O +
total O +
antioxidant O +
reserves O +
were O +
also O +
observed O +
in O +
the O +
skin O +
of O +
DMBA B-Chemical -
- O -
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical -
- O -
exposed O +
mice O -
. O +

These O +
results O +
suggest O +
that O +
Cum B-Chemical -
- I-Chemical -
OOH I-Chemical -
- O -
induced O +
carcinogenesis O +
is O +
accompanied O +
by O +
increased O +
AP-1 O +
activation O +
and O +
changes O +
in O +
antioxidant O +
status O -
. O +

RUNX1 O +
DNA O -
- O -
binding O +
mutations O +
and O +
RUNX1-PRDM16 O +
cryptic O +
fusions O +
in O +
BCR O -
- O -
ABL+ O +
leukemias O +
are O +
frequently O +
associated O +
with O +
secondary O +
trisomy O +
21 O +
and O +
may O +
contribute O +
to O +
clonal O +
evolution O +
and O +
imatinib B-Chemical +
resistance O -
. O +

Acquired O +
molecular O +
abnormalities O +
( O -
mutations O +
or O +
chromosomal O +
translocations O -
) O +
of O +
the O +
RUNX1 O +
transcription O +
factor O +
gene O +
are O +
frequent O +
in O +
acute O +
myeloblastic O +
leukemias O +
( O -
AMLs O -
) O +
and O +
in O +
therapy O -
- O -
related O +
myelodysplastic O +
syndromes O -
, O +
but O +
rarely O +
in O +
acute O +
lymphoblastic O +
leukemias O +
( O -
ALLs O -
) O +
and O +
chronic O +
myelogenous O +
leukemias O +
( O -
CMLs O -
) O -
. O +

Among O +
18 O +
BCR O -
- O -
ABL+ O +
leukemias O +
presenting O +
acquired O +
trisomy O +
of O +
chromosome O +
21 O -
, O +
we O +
report O +
a O +
high O +
frequency O +
( O -
33 O -
% O -
) O +
of O +
recurrent O +
point O +
mutations O +
( O -
4 O +
in O +
myeloid O +
blast O +
crisis O +
[ O -
BC O -
] O +
CML O +
and O +
one O +
in O +
chronic O +
phase O +
CML O -
) O +
within O +
the O +
DNA O -
- O -
binding O +
region O +
of O +
RUNX1 O -
. O +

We O +
did O +
not O +
found O +
any O +
mutation O +
in O +
de O +
novo O +
BCR O -
- O -
ABL+ O +
ALLs O +
or O +
lymphoid O +
BC O +
CML O -
. O +

Emergence O +
of O +
the O +
RUNX1 O +
mutations O +
was O +
detected O +
at O +
diagnosis O +
or O +
before O +
the O +
acquisition O +
of O +
trisomy O +
21 O +
during O +
disease O +
progression O -
. O +

In O +
addition O -
, O +
we O +
also O +
report O +
a O +
high O +
frequency O +
of O +
cryptic O +
chromosomal O +
RUNX1 O +
translocation O +
to O +
a O +
novel O +
recently O +
described O +
gene O +
partner O -
, O +
PRDM16 O +
on O +
chromosome O +
1p36 O -
, O +
for O +
3 O +
( O -
21.4 O -
% O -
) O +
of O +
14 O +
investigated O +
patients O -
: O +
2 O +
myeloid O +
BC O +
CMLs O +
and O -
, O +
for O +
the O +
first O +
time O -
, O +
1 O +
therapy O -
- O -
related O +
BCR O -
- O -
ABL+ O +
ALL O -
. O +

Two O +
patients O +
presented O +
both O +
RUNX1 O +
mutations O +
and O +
RUNX1-PRDM16 O +
fusion O -
. O +

These O +
events O +
are O +
associated O +
with O +
a O +
short O +
survival O +
and O +
support O +
the O +
concept O +
of O +
a O +
cooperative O +
effect O +
of O +
BCR O -
- O -
ABL O +
with O +
molecular O +
RUNX1 O +
abnormalities O +
on O +
the O +
differentiation O +
arrest O +
phenotype O +
observed O +
during O +
progression O +
of O +
CML O +
and O +
in O +
BCR O -
- O -
ABL+ O +
ALL O -
. O +

Hematogenous O +
metastasis O +
in O +
gastric O +
cancer O +
requires O +
isolated O +
tumor O +
cells O +
and O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
receptor-1 O -
. O +

PURPOSE O -
: O +
Recent O +
studies O +
of O +
cancer O +
metastasis O +
have O +
focused O +
on O +
the O +
role O +
of O +
premetastatic O +
gene O +
expression O +
and O +
circulating O +
tumor O +
cells O -
. O +

We O +
did O +
a O +
blind O +
prospective O +
study O +
in O +
gastric O +
cancer O +
to O +
assess O +
the O +
significance O +
of O +
isolated O +
tumor O +
cells O +
( O -
ITC O -
) O +
and O +
to O +
test O +
the O +
hypothesis O +
that O +
vascular O +
endothelial O +
growth O +
factor O +
receptor-1 O +
( O -
VEGFR-1 O -
) O +
is O +
expressed O +
within O +
the O +
bone O +
marrow O +
at O +
tumor O -
- O -
specific O -
, O +
premetastatic O +
sites O -
. O +

EXPERIMENTAL O +
DESIGN O -
: O +
Both O +
bone O +
marrow O +
and O +
peripheral O +
blood O +
samples O +
from O +
810 O +
gastric O +
cancer O +
patients O +
were O +
collected O +
at O +
the O +
Central O +
Hospital O -
, O +
National O +
Cancer O +
Center O +
( O -
Tokyo O -
, O +
Japan O -
) O -
. O +

The O +
samples O +
were O +
transferred O +
to O +
Kyushu O +
University O +
Hospital O +
( O -
Beppu O -
, O +
Japan O -
) O +
where O +
they O +
were O +
analyzed O +
by O +
quantitative O +
real O -
- O -
time O +
reverse O +
transcription O -
- O -
PCR O +
for O +
three O +
epithelial O +
cell O +
markers O -
, O +
carcinoembryonic O +
antigen O -
, O +
cytokeratin-19 O -
, O +
and O +
cytokeratin-7 O -
, O +
as O +
well O +
as O +
VEGFR-1 O -
. O +

RESULTS O -
: O +
ITCs O +
were O +
observed O +
in O +
peripheral O +
blood O +
and O +
bone O +
marrow O +
even O +
in O +
early O +
stages O +
of O +
gastric O +
cancer O -
. O +

The O +
frequency O +
of O +
ITC O +
in O +
bone O +
marrow O +
was O +
significantly O +
associated O +
with O +
the O +
stage O +
of O +
disease O +
by O +
ANOVA O +
( O -
P O +
< O +
0.01 O -
) O -
. O +

Gastric O +
cancer O +
metastasized O +
when O +
ITCs O +
were O +
observed O +
in O +
the O +
presence O +
of O +
VEGFR-1 O -
. O +

In O +
the O +
380 O +
patients O +
who O +
were O +
ITC O +
negative O +
and O +
showed O +
low O +
VEGFR-1 O +
expression O -
, O +
synchronous O +
( O -
at O +
the O +
time O +
of O +
surgery O -
) O +
and O +
heterochronous O +
( O -
recurrent O -
) O +
metastases O +
were O +
not O +
observed O -
. O +

CONCLUSIONS O -
: O +
ITCs O +
circulate O +
even O +
in O +
early O +
stages O +
of O +
disease O -
. O +

Furthermore O -
, O +
elevated O +
expression O +
of O +
VEGFR-1 O +
facilitates O +
the O +
establishment O +
of O +
hematogenous O +
metastases O +
in O +
gastric O +
cancer O -
. O +

This O +
study O +
indicates O +
that O +
the O +
simultaneous O +
presence O +
of O +
ITC O +
and O +
VEGFR-1 O +
expression O +
at O +
premetastatic O +
sites O +
is O +
clinically O +
significant O +
for O +
disease O +
progression O -
. O +

Serum O +
and O +
urine O +
levels O +
of O +
interleukin-8 O +
in O +
patients O +
with O +
non O -
- O -
Hodgkin O -
's O +
lymphoma O -
. O +

Angiogenesis O +
plays O +
an O +
important O +
role O +
in O +
many O +
types O +
of O +
cancer O -
. O +

Interleukin-8 O +
( O -
IL-8 O -
) O +
is O +
known O +
to O +
be O +
a O +
pro O -
- O -
inflammatory O +
and O +
pro O -
- O -
angiogenic O +
cytokine O -
, O +
and O +
IL-8 O +
has O +
been O +
reported O +
to O +
be O +
associated O +
with O +
tumor O +
progression O -
, O +
prognosis O +
and O +
survival O +
in O +
several O +
types O +
of O +
cancers O -
. O +

However O -
, O +
the O +
role O +
of O +
IL-8 O +
in O +
non O -
- O -
Hodgkin O -
's O +
lymphoma O +
( O -
NHL O -
) O +
has O +
not O +
been O +
fully O +
determined O -
. O +

Here O -
, O +
we O +
evaluated O +
the O +
usefulness O +
of O +
measuring O +
serum O +
and O +
urine O +
IL-8 O +
levels O +
in O +
patients O +
with O +
NHL O -
. O +

We O +
developed O +
reference O +
intervals O +
for O +
serum O +
and O +
urine O +
IL-8 O +
level O +
in O +
131 O +
control O +
individuals O -
. O +

We O +
measured O +
serum O +
IL-8 O +
and O +
urine O +
IL-8 O +
levels O +
in O +
patients O +
with O +
NHL O -
, O +
and O +
we O +
compared O +
the O +
concentrations O +
with O +
those O +
of O +
control O +
individuals O -
. O +

The O +
reference O +
intervals O +
for O +
serum O +
IL-8 O +
and O +
urine O +
IL-8 O +
corrected O +
by O +
creatinine B-Chemical +
( O -
Cr B-Chemical -
) O +
were O +
15.9 O -
- O -
430.3 O +
pg O -
/ O -
mL O +
and O +
0.0 O -
- O -
28.4 O +
pg O -
/ O -
mg O +
Cr B-Chemical -
, O +
respectively O -
. O +

The O +
concentrations O +
of O +
urine O +
IL-8 O -
/ O -
Cr B-Chemical +
were O +
significantly O +
higher O +
in O +
patients O +
than O +
in O +
controls O +
( O -
48.9+ O -
/ O -
-194.4 O +
vs. O +
5.2+ O -
/ O -
-13.8 O +
pg O -
/ O -
mg O +
Cr B-Chemical -
, O +
P O +
less O +
than O +
0.001 O -
) O -
. O +

However O -
, O +
there O +
were O +
no O +
significant O +
differences O +
in O +
serum O +
IL-8 O +
concentrations O +
between O +
NHL O +
patients O +
and O +
controls O +
( O -
159.2+ O -
/ O -
-40.4 O +
vs. O +
99.6+ O -
/ O -
-107.1 O +
pg O -
/ O -
mL O -
; O +
P=0.099 O -
) O -
. O +

Receiver O +
operating O +
characteristic O +
( O -
ROC O -
) O +
analysis O +
gave O +
0.83 O +
and O +
0.43 O +
ROC O +
area O +
values O +
for O +
urine O +
IL-8 O -
/ O -
Cr B-Chemical +
and O +
serum O +
IL-8 O -
, O +
respectively O -
. O +

There O +
was O +
no O +
correlation O +
between O +
the O +
serum O +
and O +
urine O +
concentrations O +
of O +
IL-8 O +
and O +
clinical O +
variables O -
, O +
the O +
only O +
exception O +
being O +
the O +
international O +
prognostic O +
index O +
( O -
IPI O -
) O -
, O +
which O +
showed O +
a O +
marginal O +
correlation O +
with O +
urine O +
IL-8 O -
/ O -
Cr B-Chemical +
levels O +
( O -
P=0.07 O -
) O -
. O +

This O +
study O +
indicated O +
that O +
urine O +
IL-8 O -
/ O -
Cr B-Chemical +
levels O +
might O +
be O +
useful O +
as O +
a O +
diagnostic O +
marker O +
of O +
NHL O -
. O +

Contemporary O +
perspectives O +
on O +
vital O +
pulp O +
therapy O -
: O +
views O +
from O +
the O +
endodontists O +
and O +
pediatric O +
dentists O -
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
determine O +
the O +
level O +
of O +
agreement O +
between O +
pediatric O +
dentists O +
and O +
endodontists O +
at O +
a O +
pulp O +
therapy O +
symposium O +
conjointly O +
sponsored O +
by O +
the O +
American O +
Association O +
of O +
Endodontists O +
( O -
AAE O -
) O +
and O +
the O +
American O +
Academy O +
of O +
Pediatric O +
Dentistry O +
( O -
AAPD O -
) O +
on O +
November O +
2 O -
- O -
3 O -
, O +
2007 O -
. O +

Presymposium O +
and O +
postsymposium O +
tests O +
were O +
administered O -
, O +
and O +
respondent O +
answers O +
were O +
compared O +
between O +
pediatric O +
dentists O +
and O +
endodontists O -
. O +

Opinions O +
on O +
3 O +
areas O +
were O +
sought O -
: O +
pulp O +
therapy O +
for O +
cariously O +
involved O +
primary O +
teeth O -
; O +
indirect O +
pulp O +
treatment O +
( O -
IPT O -
) O +
for O +
cariously O +
involved O +
immature O +
permanent O +
teeth O -
; O +
and O +
innovative O +
treatment O +
options O +
including O +
pulpal O +
revascularization O +
and O +
regeneration O -
. O +

Results O +
were O +
analyzed O +
with O +
chi2 O +
tests O -
. O +

Comparisons O +
of O +
presymposium O +
and O +
postsymposium O +
responses O +
and O +
between O +
the O +
2 O +
groups O +
of O +
attendees O +
indicated O +
that O +
the O +
pediatric O +
dentistry O +
and O +
endodontic O +
communities O +
agree O +
that O +
formocresol B-Chemical +
will O +
be O +
replaced O +
as O +
a O +
primary O +
tooth O +
pulpotomy O +
agent O -
, O +
that O +
mineral B-Chemical +
trioxide I-Chemical +
is O +
the O +
first O +
choice O +
to O +
take O +
its O +
place O -
, O +
that O +
IPT O +
in O +
primary O +
teeth O +
holds O +
hope O +
as O +
a O +
replacement O +
for O +
pulpotomy O -
, O +
and O +
that O +
IPT O +
is O +
an O +
acceptable O +
pulp O +
therapy O +
technique O +
for O +
cariously O +
involved O +
young O +
permanent O +
teeth O -
. O +

Both O +
groups O +
believe O +
that O +
pulp O +
revascularization O +
and O +
regeneration O +
will O +
be O +
viable O +
treatment O +
modalities O +
in O +
the O +
future O -
. O +

The O +
AAE O +
and O +
the O +
AAPD O +
are O +
positioned O +
to O +
begin O +
preparation O +
of O +
best O +
practice O +
guidelines O +
that O +
share O +
common O +
language O +
and O +
treatment O +
recommendations O +
for O +
pulp O +
therapies O +
performed O +
by O +
both O +
specialties O -
. O +

Artemisinin B-Chemical +
inhibits O +
tumor O +
lymphangiogenesis O +
by O +
suppression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
C. O +
We O +
have O +
previously O +
reported O +
that O +
dihydroartemisinin B-Chemical +
is O +
found O +
to O +
have O +
a O +
potent O +
ability O +
in O +
influencing O +
lymphatic O +
endothelial O +
cell O +
migration O +
and O +
tube O +
formation O -
. O +

In O +
this O +
study O -
, O +
we O +
investigated O +
the O +
effect O +
of O +
artemisinin B-Chemical +
on O +
tumor O +
growth O -
, O +
lymphangiogenesis O -
, O +
metastasis O +
and O +
survival O +
in O +
mouse O +
Lewis O +
lung O +
carcinoma O +
( O -
LLC O -
) O +
models O -
. O +

We O +
found O +
that O +
orally O +
administered O +
artemisinin B-Chemical +
inhibited O +
lymph O +
node O +
and O +
lung O +
metastasis O +
and O +
prolonged O +
survival O +
without O +
retarding O +
tumor O +
growth O -
. O +

Consistent O +
with O +
the O +
decrease O +
in O +
lymph O +
node O +
metastasis O -
, O +
tumor O +
lymphangiogenesis O +
and O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
C O +
( O -
VEGF O -
- O -
C O -
) O +
was O +
significantly O +
decreased O +
in O +
artemisinin B-Chemical -
- O -
treated O +
mice O -
, O +
as O +
compared O +
to O +
control O +
mice O -
. O +

Furthermore O -
, O +
IL-1beta O -
- O -
induced O +
p38 O +
mitogen O -
- O -
activated O +
protein O +
kinase O +
( O -
MAPK O -
) O +
activation O +
and O +
upregulation O +
of O +
VEGF O -
- O -
C O +
mRNA O +
and O +
protein O +
in O +
LLC O +
cells O +
was O +
also O +
suppressed O +
by O +
artemisinin B-Chemical +
or O +
by O +
the O +
p38 O +
MAPK O +
inhibitor O +
SB-203580 B-Chemical -
, O +
suggesting O +
that O +
p38 O +
MAPK O +
could O +
serve O +
as O +
a O +
mediator O +
of O +
proinflammatory O +
cytokine O -
- O -
induced O +
VEGF O -
- O -
C O +
expression O -
. O +

These O +
data O +
indicate O +
that O +
artemisinin B-Chemical +
may O +
be O +
useful O +
for O +
the O +
prevention O +
of O +
lymph O +
node O +
metastasis O +
by O +
downregulating O +
VEGF O -
- O -
C O +
and O +
reducing O +
tumor O +
lymphangiogenesis O -
. O +

Allogeneic O +
injection O +
of O +
fetal O +
membrane O -
- O -
derived O +
mesenchymal O +
stem O +
cells O +
induces O +
therapeutic O +
angiogenesis O +
in O +
a O +
rat O +
model O +
of O +
hind O +
limb O +
ischemia O -
. O +

Bone O +
marrow O -
- O -
derived O +
mesenchymal O +
stem O +
cells O +
( O -
BM O -
- O -
MSC O -
) O +
have O +
been O +
demonstrated O +
to O +
be O +
an O +
attractive O +
therapeutic O +
cell O +
source O +
for O +
tissue O +
regeneration O +
and O +
repair O -
. O +

However O -
, O +
it O +
remains O +
unknown O +
whether O +
or O +
not O +
allogeneic O +
transplantation O +
of O +
mesenchymal O +
stem O +
cells O +
( O -
MSC O -
) O +
derived O +
from O +
fetal O +
membranes O +
( O -
FM O -
) O -
, O +
which O +
are O +
generally O +
discarded O +
as O +
medical O +
waste O +
after O +
delivery O -
, O +
has O +
therapeutic O +
potential O -
. O +

FM O -
- O -
MSC O +
were O +
obtained O +
from O +
Lewis O +
rats O +
and O +
had O +
surface O +
antigen O +
expression O +
and O +
multipotent O +
potential O +
partly O +
similar O +
to O +
those O +
of O +
BM O -
- O -
MSC O -
. O +

Compared O +
with O +
BM O -
- O -
MSC O -
, O +
FM O -
- O -
MSC O +
secreted O +
a O +
comparable O +
amount O +
of O +
hepatocyte O +
growth O +
factor O +
despite O +
a O +
small O +
amount O +
of O +
vascular O +
endothelial O +
growth O +
factor O -
. O +

FM O -
- O -
MSC O +
and O +
BM O -
- O -
MSC O +
both O +
expressed O +
major O +
histocompatibility O +
complex O +
( O -
MHC O -
) O +
class O +
I O +
but O +
not O +
MHC O +
class O +
II O +
antigens O +
and O +
did O +
not O +
elicit O +
allogeneic O +
lymphocyte O +
proliferation O +
in O +
mixed O +
lymphocyte O +
culture O -
. O +

FM O -
- O -
MSC O +
or O +
BM O -
- O -
MSC O +
obtained O +
from O +
Lewis O +
rats O +
were O +
injected O +
into O +
a O +
MHC O -
- O -
mismatched O +
August O -
- O -
Copenhagen O -
- O -
Irish O +
rat O +
model O +
of O +
hind O +
limb O +
ischemia O -
. O +

Three O +
weeks O +
after O +
injection O -
, O +
blood O +
perfusion O +
and O +
capillary O +
density O +
were O +
significantly O +
higher O +
in O +
the O +
FM O -
- O -
MSC O +
and O +
BM O -
- O -
MSC O +
groups O +
than O +
in O +
the O +
phosphate B-Chemical -
- I-Chemical -
buffered I-Chemical +
saline I-Chemical +
group O -
, O +
and O +
allogeneic O +
FM O -
- O -
MSC O +
and O +
BM O -
- O -
MSC O +
were O +
still O +
observed O -
. O +

In O +
nonischemic O +
hind O +
limb O +
tissues O -
, O +
allogeneic O +
FM O -
- O -
MSC O +
and O +
BM O -
- O -
MSC O +
injection O +
were O +
associated O +
with O +
a O +
comparatively O +
small O +
amount O +
of O +
T O +
lymphocyte O +
infiltration O -
, O +
compared O +
with O +
the O +
injection O +
of O +
allogeneic O +
splenic O +
lymphocytes O -
. O +

In O +
conclusion O -
, O +
allogeneic O +
FM O -
- O -
MSC O +
injection O +
did O +
not O +
elicit O +
a O +
lymphocyte O +
proliferative O +
response O +
and O +
provided O +
significant O +
improvement O +
in O +
a O +
rat O +
model O +
of O +
hind O +
limb O +
ischemia O -
, O +
comparable O +
to O +
the O +
response O +
to O +
BM O -
- O -
MSC O -
. O +

Thus O -
, O +
allogeneic O +
injection O +
of O +
FM O -
- O -
MSC O +
may O +
be O +
a O +
new O +
therapeutic O +
strategy O +
for O +
the O +
treatment O +
of O +
severe O +
peripheral O +
vascular O +
disease O -
. O +

Disclosure O +
of O +
potential O +
conflicts O +
of O +
interest O +
is O +
found O +
at O +
the O +
end O +
of O +
this O +
article O -
. O +

Bevacizumab B-Chemical +
and O +
irinotecan B-Chemical +
therapy O +
in O +
glioblastoma O +
multiforme O -
: O +
a O +
series O +
of O +
13 O +
cases O -
. O +

OBJECT O -
: O +
Endothelial O +
proliferation O +
has O +
been O +
recognized O +
as O +
a O +
marker O +
of O +
high O -
- O -
grade O +
or O +
aggressive O +
glioma O -
. O +

Bevacizumab B-Chemical +
is O +
a O +
humanized O +
immunoglobulin O +
G1 O +
monoclonal O +
antibody O +
to O +
vascular O +
endothelial O +
growth O +
factor O +
that O +
has O +
been O +
shown O +
to O +
have O +
activity O +
in O +
malignant O +
gliomas O +
when O +
combined O +
with O +
irinotecan B-Chemical -
. O +

The O +
authors O +
report O +
on O +
a O +
case O +
series O +
of O +
13 O +
patients O +
with O +
recurrent O +
heavily O +
pretreated O +
malignant O +
glioma O +
that O +
was O +
treated O +
with O +
the O +
combination O +
of O +
bevacizumab B-Chemical +
and O +
irinotecan B-Chemical -
. O +

METHODS O -
: O +
Standard O +
therapy O +
with O +
primary O +
resection O +
followed O +
by O +
adjuvant O +
chemotherapy O +
and O +
radiation O +
had O +
failed O +
in O +
all O +
patients O -
. O +

The O +
median O +
number O +
of O +
therapies O +
applied O -
, O +
including O +
initial O +
surgery O -
, O +
was O +
5 O +
( O -
range O +
3 O -
- O -
7 O +
therapies O -
) O -
. O +

Nine O +
patients O +
were O +
started O +
on O +
bevacizumab B-Chemical +
at O +
a O +
dose O +
of O +
5 O +
mg O -
/ O -
m2 O +
every O +
2 O +
weeks O -
. O +

Four O +
patients O +
received O +
bevacizumab B-Chemical +
at O +
a O +
dose O +
of O +
10 O +
mg O -
/ O -
m2 O -
; O +
irinotecan B-Chemical +
was O +
given O +
at O +
a O +
dose O +
of O +
125 O +
mg O -
/ O -
m2 O +
every O +
week O +
for O +
3 O +
weeks O -
. O +

RESULTS O -
: O +
Of O +
the O +
13 O +
treated O +
patients O -
, O +
10 O +
( O -
77 O -
% O -
) O +
had O +
a O +
radiologically O +
demonstrated O +
partial O +
response O +
and O +
3 O +
( O -
23 O -
% O -
) O +
had O +
stable O +
disease O -
. O +

Six O +
patients O +
( O -
46 O -
% O -
) O +
had O +
a O +
clinical O +
response O -
. O +

The O +
median O +
time O +
to O +
disease O +
progression O +
while O +
on O +
treatment O +
was O +
24 O +
weeks O -
. O +

The O +
median O +
overall O +
survival O +
was O +
27 O +
weeks O -
. O +

The O +
disease O +
progressed O +
in O +
8 O +
patients O -
, O +
despite O +
an O +
initial O +
response O -
. O +

Five O +
patients O +
are O +
still O +
responding O +
to O +
therapy O -
. O +

Six O +
of O +
the O +
8 O +
patients O +
whose O +
disease O +
progressed O +
have O +
died O -
. O +

Bevacizumab B-Chemical +
was O +
discontinued O +
in O +
2 O +
patients O +
because O +
of O +
nonfatal O +
intracranial O +
bleeding O -
. O +

CONCLUSIONS O -
: O +
The O +
combination O +
of O +
bevacizumab B-Chemical +
and O +
irinotecan B-Chemical +
is O +
safe O +
and O +
has O +
excellent O +
activity O +
even O +
in O +
this O +
relapsed O -
, O +
heavily O +
pretreated O +
population O +
of O +
patients O +
with O +
high O -
- O -
grade O +
malignant O +
glioma O -
, O +
most O +
of O +
whom O +
would O +
not O +
be O +
candidates O +
for O +
clinical O +
trials O -
. O +

Clinical O +
significance O +
of O +
chicken O +
ovalbumin O +
upstream O +
promoter O -
- O -
transcription O +
factor O +
II O +
expression O +
in O +
human O +
colorectal O +
cancer O -
. O +

Chicken O +
ovalbumin O +
upstream O +
promoter O -
- O -
transcription O +
factor O +
II O +
( O -
COUP O -
- O -
TFII O -
) O +
plays O +
an O +
essential O +
role O +
in O +
angiogenesis O +
and O +
development O -
. O +

A O +
previous O +
study O +
showed O +
that O +
the O +
expression O +
of O +
COUP O -
- O -
TFII O +
enhanced O +
invasiveness O +
of O +
human O +
lung O +
carcinoma O +
cells O -
. O +

However O -
, O +
no O +
published O +
data O +
are O +
available O +
concerning O +
the O +
biological O +
and O +
clinical O +
significance O +
of O +
COUP O -
- O -
TFII O +
expression O +
in O +
colorectal O +
cancer O -
. O +

Thus O -
, O +
our O +
objective O +
was O +
to O +
explore O +
the O +
expression O +
of O +
COUP O -
- O -
TFII O +
in O +
colorectal O +
cancer O +
as O +
well O +
as O +
its O +
association O +
with O +
clinicopathological O +
features O -
, O +
and O +
to O +
evaluate O +
the O +
role O +
of O +
COUP O -
- O -
TFII O +
as O +
a O +
prognostic O +
indicator O +
in O +
colorectal O +
cancer O -
. O +

We O +
investigated O +
the O +
presence O +
of O +
COUP O -
- O -
TFII O +
in O +
human O +
colorectal O +
cancer O +
tissues O +
and O +
adjacent O +
normal O +
tissues O +
from O +
95 O +
primary O +
colorectal O +
cancer O +
patients O +
by O +
immunohistochemistry O -
. O +

The O +
correlation O +
between O +
the O +
expression O +
of O +
COUP O -
- O -
TFII O +
and O +
clinicopathologic O +
features O +
was O +
investigated O -
. O +

The O +
3-year O +
disease O -
- O -
free O +
survival O +
( O -
DFS O -
) O +
and O +
overall O +
survival O +
( O -
OS O -
) O +
of O +
patients O +
with O +
tumors O +
expressing O +
different O +
levels O +
of O +
COUP O -
- O -
TFII O +
were O +
evaluated O +
by O +
the O +
Kaplan O -
- O -
Meier O +
method O -
. O +

No O +
significant O +
correlation O +
was O +
found O +
between O +
COUP O -
- O -
TFII O +
expression O +
and O +
age O +
at O +
surgery O -
, O +
gender O -
, O +
histopathologic O +
differentiation O -
, O +
vessel O +
invasion O -
, O +
carcinoembryonic O +
antigen O +
( O -
CEA O -
) O -
, O +
or O +
nodal O +
involvement O -
. O +

However O -
, O +
survival O +
analysis O +
showed O +
that O +
the O +
COUP O -
- O -
TFII O -
- O -
positive O +
group O +
had O +
a O +
significantly O +
better O +
OS O +
compared O +
to O +
COUP O -
- O -
TFII O -
- O -
negative O +
group O +
( O -
80.4 O -
% O +
vs. O +
57.7 O -
% O -
, O +
P=0.0491 O -
) O -
. O +

Based O +
on O +
our O +
results O -
, O +
COUP O -
- O -
TFII O +
may O +
represent O +
a O +
biomarker O +
for O +
good O +
prognosis O +
in O +
colorectal O +
cancer O -
. O +

Rab O +
GTPase O +
regulation O +
of O +
VEGFR2 O +
trafficking O +
and O +
signaling O +
in O +
endothelial O +
cells O -
. O +

OBJECTIVE O -
: O +
Vascular O +
endothelial O +
growth O +
factor O +
receptor O +
2 O +
( O -
VEGFR2 O -
) O +
is O +
a O +
receptor O +
tyrosine O +
kinase O +
that O +
regulates O +
vascular O +
physiology O -
. O +

However O -
, O +
mechanism O -
( O -
s O -
) O +
by O +
which O +
VEGFR2 O +
signaling O +
and O +
trafficking O +
is O +
coordinated O +
are O +
not O +
clear O -
. O +

Here O -
, O +
we O +
have O +
tested O +
endocytic O +
Rab O +
GTPases O +
for O +
regulation O +
of O +
VEGFR2 O +
trafficking O +
and O +
signaling O +
linked O +
to O +
endothelial O +
cell O +
migration O -
. O +

METHODS O +
AND O +
RESULTS O -
: O +
Quiescent O +
VEGFR2 O +
displays O +
endosomal O +
localization O +
and O +
colocalization O +
with O +
the O +
Rab5a O +
GTPase O -
, O +
an O +
early O +
endosome O +
fusion O +
regulator O -
. O +

Expression O +
of O +
GTP B-Chemical +
or O +
GDP B-Chemical -
- O -
bound O +
Rab5a O +
mutants O +
block O +
activated O +
VEGFR2 O +
trafficking O +
and O +
degradation O -
. O +

Manipulation O +
of O +
Rab7a O +
GTPase O +
activity O +
associated O +
with O +
late O +
endosomes O +
using O +
overexpression O +
of O +
wild O -
- O -
type O +
or O +
mutant O +
proteins O +
blocks O +
activated O +
VEGFR2 O +
trafficking O +
and O +
degradation O -
. O +

Depletion O +
of O +
Rab7a O +
decreased O +
VEGFR2 O +
Y1175 O +
phosphorylation O +
but O +
increased O +
p42 O -
/ O -
44 O +
( O -
pERK1 O -
/ O -
2 O -
) O +
MAPK O +
phosphorylation O -
. O +

Endothelial O +
cell O +
migration O +
was O +
increased O +
by O +
Rab5a O +
depletion O +
but O +
decreased O +
by O +
Rab7a O +
depletion O -
. O +

CONCLUSIONS O -
: O +
Rab5a O +
and O +
Rab7a O +
regulate O +
VEGFR2 O +
trafficking O +
toward O +
early O +
and O +
late O +
endosomes O -
. O +

Our O +
data O +
suggest O +
that O +
VEGFR2-mediated O +
regulation O +
of O +
endothelial O +
function O +
is O +
dependent O +
on O +
different O +
but O +
specific O +
Rab O -
- O -
mediated O +
GTP B-Chemical +
hydrolysis O +
activity O +
required O +
for O +
endosomal O +
trafficking O -
. O +

FOXO3a O +
elicits O +
a O +
pro O -
- O -
apoptotic O +
transcription O +
program O +
and O +
cellular O +
response O +
to O +
human O +
lung O +
carcinogen O +
nicotine B-Chemical -
- I-Chemical -
derived I-Chemical +
nitrosaminoketone I-Chemical +
( O -
NNK B-Chemical -
) O -
. O +

Long O -
- O -
term O +
carcinogen O +
exposure O +
exerts O +
continuous O +
pressure O +
on O +
key O +
mechanisms O +
that O +
repair O +
or O +
eliminate O +
carcinogen O -
- O -
damaged O +
cells O +
giving O +
rise O +
to O +
selective O +
failures O +
that O +
contribute O +
to O +
lung O +
cancer O -
. O +

FOXO3a O +
is O +
a O +
transcription O +
factor O +
that O +
elicits O +
a O +
protective O +
response O +
to O +
diverse O +
cellular O +
stresses O -
. O +

Although O +
implicated O +
as O +
a O +
tumor O +
suppressor O -
, O +
its O +
role O +
in O +
sporadic O +
cancer O +
is O +
uncertain O -
. O +

We O +
recently O +
observed O +
that O +
FOXO3a O +
gene O +
inactivation O +
occurs O +
frequently O +
in O +
carcinogen O -
- O -
induced O +
lung O +
adenocarcinoma O +
( O -
LAC O -
) O -
. O +

This O +
suggests O +
that O +
FOXO3a O +
may O +
play O +
a O +
role O +
in O +
LAC O +
suppression O +
by O +
eliciting O +
a O +
protective O +
response O +
to O +
carcinogenic O +
stress O -
. O +

Here O +
we O +
investigated O +
this O +
possibility O +
by O +
examining O +
the O +
role O +
of O +
FOXO3a O +
in O +
the O +
cellular O +
response O +
to O +
nicotine B-Chemical -
- I-Chemical -
derived I-Chemical +
nitrosaminoketone I-Chemical +
( O -
NNK B-Chemical -
) O -
, O +
a O +
lung O +
carcinogen O +
implicated O +
as O +
a O +
cause O +
of O +
human O +
LAC O -
. O +

We O +
show O +
that O +
restoration O +
of O +
FOXO3a O +
in O +
FOXO3a O -
- O -
deficient O +
LAC O +
cells O +
increases O +
sensitivity O +
to O +
apoptosis O +
caused O +
by O +
a O +
DNA O -
- O -
damaging O +
intermediate O +
of O +
NNK B-Chemical -
. O +

Prior O +
to O +
this O +
cellular O +
outcome O -
, O +
FOXO3a O +
is O +
functionally O +
activated O +
and O +
mediates O +
a O +
large O -
- O -
scale O +
transcription O +
program O +
in O +
response O +
to O +
this O +
damage O +
involving O +
a O +
significant O +
modulation O +
of O +
440 O +
genes O -
. O +

Genes O +
most O +
significantly O +
represented O +
in O +
this O +
program O +
are O +
those O +
with O +
roles O +
in O +
cell O +
growth O +
and O +
proliferation O -
> O -
protein O +
synthesis O -
> O -
gene O +
expression O -
> O -
cell O +
death O -
> O -
cell O +
cycle O -
. O +

The O +
results O +
of O +
this O +
study O +
show O +
that O +
FOXO3a O +
directs O +
an O +
anti O -
- O -
carcinogenic O +
transcription O +
program O +
that O +
culminates O +
in O +
the O +
elimination O +
of O +
carcinogen O -
- O -
damaged O +
cells O -
. O +

This O +
suggests O +
that O +
FOXO3a O +
is O +
a O +
potential O +
suppressor O +
of O +
carcinogenic O +
damage O +
in O +
LAC O -
. O +

The O +
EGFR O -
- O -
GEP100-Arf6-AMAP1 O +
signaling O +
pathway O +
specific O +
to O +
breast O +
cancer O +
invasion O +
and O +
metastasis O -
. O +

Tumors O +
are O +
tissue O -
- O -
specific O +
diseases O -
, O +
and O +
their O +
mechanisms O +
of O +
invasion O +
and O +
metastasis O +
are O +
highly O +
diverse O -
. O +

In O +
breast O +
cancer O -
, O +
biomarkers O +
that O +
specifically O +
correlate O +
with O +
the O +
invasive O +
phenotypes O +
have O +
not O +
been O +
clearly O +
identified O -
. O +

A O +
small O +
GTPase O +
Arf6 O +
primarily O +
regulates O +
recycling O +
of O +
plasma O +
membrane O +
components O -
. O +

We O +
have O +
shown O +
that O +
Arf6 O +
and O +
its O +
effector O +
AMAP1 O +
( O -
DDEF1 O -
, O +
DEF1 O -
, O +
ASAP1 O +
and O +
centaurin O +
beta4 O -
) O +
are O +
abnormally O +
overexpressed O +
in O +
some O +
breast O +
cancers O +
and O +
used O +
for O +
their O +
invasion O +
and O +
metastasis O -
. O +

Overexpression O +
of O +
these O +
proteins O +
is O +
independent O +
of O +
the O +
transcriptional O +
upregulation O +
of O +
their O +
genes O -
, O +
and O +
occurs O +
only O +
in O +
highly O +
malignant O +
breast O +
cancer O +
cells O -
. O +

We O +
recently O +
identified O +
GEP100 O +
( O -
BRAG2 O -
) O +
to O +
be O +
responsible O +
for O +
the O +
Arf6 O +
activation O +
to O +
induce O +
invasion O +
and O +
metastasis O -
, O +
by O +
directly O +
binding O +
to O +
ligand O -
- O -
activated O +
epidermal O +
growth O +
factor O +
receptor O +
( O -
EGFR O -
) O -
. O +

A O +
series O +
of O +
our O +
studies O +
revealed O +
that O +
for O +
activation O +
of O +
the O +
invasion O +
pathway O +
of O +
EGFR O -
, O +
it O +
is O +
prerequisite O +
that O +
Arf6 O +
and O +
AMAP1 O +
both O +
are O +
highly O +
overexpressed O -
, O +
and O +
that O +
EGFR O +
is O +
activated O +
by O +
ligands O -
. O +

Pathological O +
analyses O +
indicate O +
that O +
a O +
significant O +
large O +
population O +
of O +
human O +
ductal O +
cancers O +
may O +
utilize O +
the O +
EGFR O -
- O -
GEP100-Arf6-AMAP1 O +
pathway O +
for O +
their O +
malignancy O -
. O +

Microenvironments O +
have O +
been O +
highly O +
implicated O +
in O +
the O +
malignancy O +
of O +
mammary O +
tumors O -
. O +

Our O +
results O +
reveal O +
an O +
aspect O +
of O +
the O +
precise O +
molecular O +
mechanisms O +
of O +
some O +
breast O +
cancers O -
, O +
in O +
which O +
full O +
invasiveness O +
is O +
not O +
acquired O +
just O +
by O +
intracellular O +
alterations O +
of O +
cancer O +
cells O -
, O +
but O +
extracellular O +
factors O +
from O +
microenvironments O +
may O +
also O +
be O +
necessary O -
. O +

Possible O +
translation O +
of O +
our O +
knowledge O +
to O +
cancer O +
therapeutics O +
will O +
also O +
be O +
discussed O -
. O +

Dose- O +
and O +
time O -
- O -
dependent O +
effects O +
of O +
doxorubicin B-Chemical +
on O +
cytotoxicity O -
, O +
cell O +
cycle O +
and O +
apoptotic O +
cell O +
death O +
in O +
human O +
colon O +
cancer O +
cells O -
. O +

The O +
cytostatic O +
drug O +
doxorubicin B-Chemical +
is O +
a O +
well O -
- O -
known O +
chemotherapeutic O +
agent O +
which O +
is O +
used O +
in O +
treatment O +
of O +
a O +
wide O +
variety O +
of O +
cancers O -
. O +

A O +
key O +
factor O +
in O +
the O +
response O +
of O +
cancer O +
cells O +
to O +
chemotherapeutic O +
drugs O +
is O +
the O +
activation O +
of O +
the O +
apoptotic O +
pathway O -
, O +
a O +
pathway O +
that O +
is O +
often O +
impaired O +
in O +
chemoresistant O +
colon O +
cancer O +
cells O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
effects O +
of O +
doxorubicin B-Chemical +
in O +
Hct-116 O +
human O +
colon O +
carcinoma O +
cells O +
in O +
order O +
to O +
clarify O +
if O +
a O +
time O -
/ O -
concentration O +
range O +
for O +
optimal O +
doxorubicin B-Chemical -
- O -
induced O +
apoptosis O +
exists O -
. O +

We O +
compared O +
a O +
treatment O +
schedule O +
were O +
cells O +
were O +
bolus O +
incubated O +
for O +
3h O +
with O +
doxorubicin B-Chemical +
followed O +
by O +
24h O +
in O +
drug O -
- O -
free O +
medium O -
, O +
with O +
a O +
continuous O +
doxorubicin B-Chemical +
treatment O +
schedule O +
for O +
24h O -
. O +

Bolus O +
incubation O +
was O +
carried O +
out O +
to O +
determine O +
effects O +
of O +
doxorubicin B-Chemical +
accumulated O +
during O +
the O +
first O +
3h O -
, O +
whereas O +
continuous O +
incubation O +
allowed O +
further O +
( O -
continuous O -
) O +
exposure O +
to O +
doxorubicin B-Chemical -
. O +

We O +
found O +
that O +
bolus O +
( O -
3h O -
) O +
treatment O +
with O +
doxorubicin B-Chemical +
resulted O +
in O +
a O +
dose O -
- O -
dependent O +
decrease O +
of O +
viable O +
cells O +
and O +
concomitant O +
increase O +
of O +
apoptosis O -
. O +

Additionally O -
, O +
bolus O +
( O -
3h O -
) O +
doxorubicin B-Chemical +
incubation O +
led O +
to O +
phosphorylation O +
of O +
p53 O +
at O +
serine O +
392 O -
, O +
induction O +
of O +
p21 O -
, O +
G2 O +
arrest O +
and O +
increase O +
of O +
proapoptotic O +
protein O +
Bax O -
. O +

In O +
contrast O -
, O +
continuous O +
( O -
24h O -
) O +
treatment O +
with O +
doxorubicin B-Chemical +
reduced O +
the O +
number O +
of O +
living O +
cells O +
with O +
no O +
parallel O +
raise O +
in O +
the O +
amount O +
of O +
dead O +
cells O -
. O +

Continuous O +
( O -
24h O -
) O +
treatment O +
with O +
5 O +
microM O +
doxorubicin B-Chemical +
resulted O +
in O +
cell O +
cycle O +
arrest O +
in O +
G0 O -
/ O -
G1 O +
phase O +
that O +
was O +
neither O +
accompanied O +
by O +
phosphorylation O +
and O +
activation O +
of O +
p53 O +
nor O +
enhanced O +
expression O +
of O +
p21 O -
. O +

These O +
results O +
suggest O +
that O +
doxorubicin B-Chemical +
is O +
able O +
to O +
induce O +
cell O +
death O +
by O +
apoptosis O +
only O +
at O +
particular O +
dose O +
and O +
treatment O +
conditions O +
and O +
imply O +
a O +
completely O +
different O +
cellular O +
response O +
following O +
bolus O +
or O +
continuous O +
exposure O +
to O +
doxorubicin B-Chemical -
. O +

Relationship O +
and O +
prognostic O +
significance O +
of O +
SPARC O +
and O +
VEGF O +
protein O +
expression O +
in O +
colon O +
cancer O -
. O +

BACKGROUND O -
: O +
SPARC O +
( O -
secreted O +
protein O -
, O +
acidic O +
and O +
rich O +
in O +
cysteine O -
) O +
is O +
closely O +
related O +
with O +
the O +
progress O -
, O +
invasion O +
and O +
metastasis O +
of O +
malignant O +
tumor O +
and O +
angiogenesis O -
. O +

METHODS O -
: O +
Using O +
human O +
colon O +
adenocarcinoma O +
tissues O +
( O -
hereinafter O +
referred O +
to O +
as O +
colon O +
cancer O -
) O +
and O +
their O +
corresponding O +
non O -
- O -
diseased O +
colon O +
from O +
114 O +
patients O -
' O +
biopsies O -
, O +
the O +
expression O +
of O +
SPARC O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O -
VEGF O -
) O +
were O +
investigated O +
by O +
immunohistochemistry O +
staining O +
to O +
assessment O +
the O +
relationship O +
between O +
SPARC O +
and O +
VEGF O -
, O +
as O +
well O +
as O +
their O +
prognostic O +
significance O +
in O +
patients O -
. O +

Evaluation O +
of O +
VEGF O +
expression O +
level O +
with O +
the O +
same O +
tissues O +
was O +
used O +
to O +
establish O +
the O +
antigenic O +
profiles O -
, O +
and O +
the O +
marker O +
of O +
CD34 O +
staining O +
was O +
used O +
as O +
an O +
indicator O +
of O +
microvessel O +
density O +
( O -
MVD O -
) O -
. O +

RESULTS O -
: O +
SPARC O +
expression O +
was O +
mainly O +
in O +
the O +
stromal O +
cells O +
surrounding O +
the O +
colon O +
cancer O -
, O +
and O +
was O +
significant O +
difference O +
in O +
those O +
tissues O +
with O +
the O +
lymph O +
node O +
metastasis O +
and O +
differentiation O +
degree O +
of O +
tumor O -
. O +

Expression O +
of O +
SPARC O +
was O +
significantly O +
correlated O +
with O +
the O +
expression O +
of O +
VEGF O +
and O +
MVD O +
in O +
colon O +
cancer O +
tissues O -
. O +

Patients O +
with O +
low O +
or O +
absence O +
expressing O +
SPARC O +
had O +
significantly O +
worse O +
overall O +
survival O +
and O +
disease O -
- O -
free O +
survival O +
in O +
a O +
Single O +
Factor O +
Analysis O -
; O +
Cox O +
Regression O +
Analysis O -
, O +
SPARC O +
emerged O +
as O +
an O +
overall O +
survival O +
and O +
disease O -
- O -
free O +
survival O +
independent O +
prognostic O +
factor O +
for O +
colon O +
cancer O -
. O +

CONCLUSION O -
: O +
The O +
low O +
expression O +
or O +
absence O +
of O +
stromal O +
SPARC O +
was O +
an O +
independent O +
prognostic O +
factor O +
for O +
poor O +
prognosis O +
of O +
colon O +
cancer O -
. O +

SPARC O +
maybe O +
involved O +
in O +
the O +
regulation O +
of O +
anti O -
- O -
angiogenesis O +
by O +
which O +
it O +
may O +
serve O +
as O +
a O +
novel O +
target O +
for O +
colon O +
cancer O +
treatment O +
as O +
well O +
as O +
a O +
novel O +
distinctive O +
marker O -
. O +

Constitutively O +
nuclear O +
FOXO3a O +
localization O +
predicts O +
poor O +
survival O +
and O +
promotes O +
Akt O +
phosphorylation O +
in O +
breast O +
cancer O -
. O +

BACKGROUND O -
: O +
The O +
PI3K O -
- O -
Akt O +
signal O +
pathway O +
plays O +
a O +
key O +
role O +
in O +
tumorigenesis O +
and O +
the O +
development O +
of O +
drug O -
- O -
resistance O -
. O +

Cytotoxic O +
chemotherapy O +
resistance O +
is O +
linked O +
to O +
limited O +
therapeutic O +
options O +
and O +
poor O +
prognosis O -
. O +

METHODOLOGY O -
/ O -
PRINCIPAL O +
FINDINGS O -
: O +
Examination O +
of O +
FOXO3a O +
and O +
phosphorylated O -
- O -
Akt O +
( O -
P O -
- O -
Akt O -
) O +
expression O +
in O +
breast O +
cancer O +
tissue O +
microarrays O +
showed O +
nuclear O +
FOXO3a O +
was O +
associated O +
with O +
lymph O +
node O +
positivity O +
( O -
p O +
= O +
0.052 O -
) O -
, O +
poor O +
prognosis O +
( O -
p O +
= O +
0.014 O -
) O -
, O +
and O +
P O -
- O -
Akt O +
expression O +
in O +
invasive O +
ductal O +
carcinoma O -
. O +

Using O +
tamoxifen B-Chemical +
and O +
doxorubicin B-Chemical -
- O -
sensitive O +
and O +
-resistant O +
breast O +
cancer O +
cell O +
lines O +
as O +
models O -
, O +
we O +
found O +
that O +
doxorubicin- B-Chemical +
but O +
not O +
tamoxifen B-Chemical -
- O -
resistance O +
is O +
associated O +
with O +
nuclear O +
accumulation O +
of O +
FOXO3a O -
, O +
consistent O +
with O +
the O +
finding O +
that O +
sustained O +
nuclear O +
FOXO3a O +
is O +
associated O +
with O +
poor O +
prognosis O -
. O +

We O +
also O +
established O +
that O +
doxorubicin B-Chemical +
treatment O +
induces O +
proliferation O +
arrest O +
and O +
FOXO3a O +
nuclear O +
relocation O +
in O +
sensitive O +
breast O +
cancer O +
cells O -
. O +

Induction O +
of O +
FOXO3a O +
activity O +
in O +
doxorubicin B-Chemical -
- O -
sensitive O +
MCF-7 O +
cells O +
was O +
sufficient O +
to O +
promote O +
Akt O +
phosphorylation O +
and O +
arrest O +
cell O +
proliferation O -
. O +

Conversely O -
, O +
knockdown O +
of O +
endogenous O +
FOXO3a O +
expression O +
reduced O +
PI3K O -
/ O -
Akt O +
activity O -
. O +

Using O +
MDA O -
- O -
MB-231 O +
cells O -
, O +
in O +
which O +
FOXO3a O +
activity O +
can O +
be O +
induced O +
by O +
4-hydroxytamoxifen B-Chemical -
, O +
we O +
showed O +
that O +
FOXO3a O +
induction O +
up O -
- O -
regulates O +
PI3K O -
- O -
Akt O +
activity O +
and O +
enhanced O +
doxorubicin B-Chemical +
resistance O -
. O +

However O +
FOXO3a O +
induction O +
has O +
little O +
effect O +
on O +
cell O +
proliferation O -
, O +
indicating O +
that O +
FOXO3a O +
or O +
its O +
downstream O +
activity O +
is O +
deregulated O +
in O +
the O +
cytotoxic O +
drug O +
resistant O +
breast O +
cancer O +
cells O -
. O +

Thus O -
, O +
our O +
results O +
suggest O +
that O +
sustained O +
FOXO3a O +
activation O +
can O +
enhance O +
hyperactivation O +
of O +
the O +
PI3K O -
/ O -
Akt O +
pathway O -
. O +

CONCLUSIONS O -
/ O -
SIGNIFICANCE O -
: O +
Together O +
these O +
data O +
suggest O +
that O +
lymph O +
node O +
metastasis O +
and O +
poor O +
survival O +
in O +
invasive O +
ductal O +
breast O +
carcinoma O +
are O +
linked O +
to O +
an O +
uncoupling O +
of O +
the O +
Akt O -
- O -
FOXO3a O +
signaling O +
axis O -
. O +

In O +
these O +
breast O +
cancers O +
activated O +
Akt O +
fails O +
to O +
inactivate O +
and O +
re O -
- O -
localize O +
FOXO3a O +
to O +
the O +
cytoplasm O -
, O +
and O +
nuclear O -
- O -
targeted O +
FOXO3a O +
does O +
not O +
induce O +
cell O +
death O +
or O +
cell O +
cycle O +
arrest O -
. O +

As O +
such O -
, O +
sustained O +
nuclear O +
FOXO3a O +
expression O +
in O +
breast O +
cancer O +
may O +
culminate O +
in O +
cancer O +
progression O +
and O +
the O +
development O +
of O +
an O +
aggressive O +
phenotype O +
similar O +
to O +
that O +
observed O +
in O +
cytotoxic O +
chemotherapy O +
resistant O +
breast O +
cancer O +
cell O +
models O -
. O +

Androgen B-Chemical +
stimulates O +
glycolysis O +
for O +
de O +
novo O +
lipid B-Chemical +
synthesis O +
by O +
increasing O +
the O +
activities O +
of O +
hexokinase O +
2 O +
and O +
6-phosphofructo-2-kinase O -
/ O -
fructose-2,6-bisphosphatase O +
2 O +
in O +
prostate O +
cancer O +
cells O -
. O +

Up O -
- O -
regulation O +
of O +
lipogenesis O +
by O +
androgen B-Chemical +
is O +
one O +
of O +
the O +
most O +
characteristic O +
metabolic O +
features O +
of O +
LNCaP O +
prostate O +
cancer O +
cells O -
. O +

The O +
present O +
study O +
revealed O +
that O +
androgen B-Chemical +
increases O +
glucose B-Chemical +
utilization O +
for O +
de O +
novo O +
lipogenesis O +
in O +
LNCaP O +
cells O +
through O +
the O +
activation O +
of O +
HK2 O +
( O -
hexokinase O +
2 O -
) O +
and O +
activation O +
of O +
the O +
cardiac O +
isoform O +
of O +
PFKFB2 O +
( O -
6-phosphofructo-2-kinase O -
/ O -
fructose-2,6-bisphosphatase O -
) O -
. O +

Activation O +
of O +
PKA O +
( O -
cAMP O -
- O -
dependent O +
protein O +
kinase O -
) O +
by O +
androgen B-Chemical +
increased O +
phosphorylation O +
of O +
CREB O +
[ O -
CRE O +
( O -
cAMP O -
- O -
response O +
element O -
) O -
-binding O +
protein O -
] O -
, O +
which O +
in O +
turn O +
bound O +
to O +
CRE O +
on O +
the O +
promoter O +
of O +
the O +
HK2 O +
gene O +
resulting O +
in O +
transcriptional O +
activation O +
of O +
the O +
HK2 O +
gene O -
. O +

Up O -
- O -
regulation O +
of O +
PFKFB2 O +
expression O +
was O +
mediated O +
by O +
the O +
direct O +
binding O +
of O +
ligand O -
- O -
activated O +
androgen B-Chemical +
receptor O +
to O +
the O +
PFKFB2 O +
promoter O -
. O +

The O +
activated O +
PI3 O -
K O +
( O -
phosphoinositide O +
3-kinase O -
) O -
/ O -
Akt O +
signalling O +
pathway O +
in O +
LNCaP O +
cells O +
contributes O +
to O +
the O +
phosphorylation O +
of O +
PFKFB2 O +
at O +
Ser466 O +
and O +
Ser483 O -
, O +
resulting O +
in O +
the O +
constitutive O +
activation O +
of O +
PFK-2 O +
( O -
6-phosphofructo-2-kinase O -
) O +
activity O -
. O +

Glucose B-Chemical +
uptake O +
and O +
lipogenesis O +
were O +
severely O +
blocked O +
by O +
knocking O -
- O -
down O +
of O +
PFKFB2 O +
using O +
siRNA O +
( O -
small O +
interfering O +
RNA O -
) O +
or O +
by O +
inhibition O +
of O +
PFK-2 O +
activity O +
with O +
LY294002 B-Chemical +
treatment O -
. O +

Taken O +
together O -
, O +
our O +
results O +
suggest O +
that O +
the O +
induction O +
of O +
de O +
novo O +
lipid B-Chemical +
synthesis O +
by O +
androgen B-Chemical +
requires O +
the O +
transcriptional O +
up O -
- O -
regulation O +
of O +
HK2 O +
and O +
PFKFB2 O -
, O +
and O +
phosphorylation O +
of O +
PFKFB2 O +
generated O +
by O +
the O +
PI3K O -
/ O -
Akt O +
signalling O +
pathway O +
to O +
supply O +
the O +
source O +
for O +
lipogenesis O +
from O +
glucose B-Chemical +
in O +
prostate O +
cancer O +
cells O -
. O +

[ O -
Expression O +
of O +
Merlin O +
protein O +
in O +
non O -
- O -
small O +
cell O +
lung O +
carcinoma O +
and O +
the O +
clinical O +
significance O -
] O -
. O +

OBJECTIVE O -
: O +
To O +
determine O +
the O +
expression O +
and O +
clinical O +
significance O +
of O +
Merlin O +
protein O +
in O +
non O -
- O -
small O +
cell O +
lung O +
cancer O +
( O -
NSCLC O -
) O -
. O +

METHODS O -
: O +
The O +
expression O +
of O +
Merlin O +
protein O +
in O +
45 O +
cases O +
of O +
NSCLC O +
and O +
adjacent O +
tissue O +
of O +
NSCLC O +
and O +
normal O +
lung O +
tissue O +
was O +
checked O +
by O +
immunohistochemistry O -
. O +

The O +
relation O +
between O +
the O +
expression O +
of O +
Merlin O +
protein O +
and O +
the O +
multiple O +
factors O +
of O +
pathological O +
type O -
, O +
gender O -
, O +
P O -
- O -
TNM O +
stage O -
, O +
differentiation O +
and O +
lymph O +
node O +
metastasis O +
was O +
analyzed O -
. O +

RESULTS O -
: O +
The O +
expression O +
rates O +
of O +
Merlin O +
protein O +
in O +
NSCLC O +
and O +
normal O +
lung O +
tissue O +
sections O +
were O +
73.33 O -
% O +
and O +
15.56 O -
% O -
, O +
respectively O +
( O -
P<0.05 O -
) O -
. O +

The O +
expression O +
of O +
Merlin O +
protein O +
was O +
not O +
associated O +
with O +
the O +
pathological O +
type O -
, O +
gender O -
, O +
P O -
- O -
TNM O +
stage O -
, O +
differentiation O +
and O +
lymph O +
node O +
metastasis O +
( O -
P>0.05 O -
) O -
. O +

CONCLUSION O -
: O +
Merlin O +
protein O +
might O +
contribute O +
to O +
the O +
initiation O +
of O +
metastasis O +
of O +
NSCLC O -
. O +

Hedgehog O +
signaling O -
: O +
networking O +
to O +
nurture O +
a O +
promalignant O +
tumor O +
microenvironment O -
. O +

In O +
addition O +
to O +
its O +
role O +
in O +
embryonic O +
development O -
, O +
the O +
Hedgehog O +
pathway O +
has O +
been O +
shown O +
to O +
be O +
an O +
active O +
participant O +
in O +
cancer O +
development O -
, O +
progression O -
, O +
and O +
metastasis O -
. O +

Although O +
this O +
pathway O +
is O +
activated O +
by O +
autocrine O +
signaling O +
by O +
Hedgehog O +
ligands O -
, O +
it O +
can O +
also O +
initiate O +
paracrine O +
signaling O +
with O +
cells O +
in O +
the O +
microenvironment O -
. O +

This O +
creates O +
a O +
network O +
of O +
Hedgehog O +
signaling O +
that O +
determines O +
the O +
malignant O +
behavior O +
of O +
the O +
tumor O +
cells O -
. O +

As O +
a O +
result O +
of O +
paracrine O +
signal O +
transmission O -
, O +
the O +
effects O +
of O +
Hedgehog O +
signaling O +
most O +
profoundly O +
influence O +
the O +
stromal O +
cells O +
that O +
constitute O +
the O +
tumor O +
microenvironment O -
. O +

The O +
stromal O +
cells O +
in O +
turn O +
produce O +
factors O +
that O +
nurture O +
the O +
tumor O -
. O +

Thus O -
, O +
such O +
a O +
resonating O +
cross O -
- O -
talk O +
can O +
amplify O +
Hedgehog O +
signaling O -
, O +
resulting O +
in O +
molecular O +
chatter O +
that O +
overall O +
promotes O +
tumor O +
progression O -
. O +

Inhibitors O +
of O +
Hedgehog O +
signaling O +
have O +
been O +
the O +
subject O +
of O +
intense O +
research O -
. O +

Several O +
of O +
these O +
inhibitors O +
are O +
currently O +
being O +
evaluated O +
in O +
clinical O +
trials O -
. O +

Here O -
, O +
we O +
review O +
the O +
role O +
of O +
the O +
Hedgehog O +
pathway O +
in O +
the O +
signature O +
characteristics O +
of O +
cancer O +
cells O +
that O +
determine O +
tumor O +
development O -
, O +
progression O -
, O +
and O +
metastasis O -
. O +

This O +
review O +
condenses O +
the O +
latest O +
findings O +
on O +
the O +
signaling O +
pathways O +
that O +
are O +
activated O +
and/or O +
regulated O +
by O +
molecules O +
generated O +
from O +
Hedgehog O +
signaling O +
in O +
cancer O +
and O +
cites O +
promising O +
clinical O +
interventions O -
. O +

Finally O -
, O +
we O +
discuss O +
future O +
directions O +
for O +
identifying O +
the O +
appropriate O +
patients O +
for O +
therapy O -
, O +
developing O +
reliable O +
markers O +
of O +
efficacy O +
of O +
treatment O -
, O +
and O +
combating O +
resistance O +
to O +
Hedgehog O +
pathway O +
inhibitors O -
. O +

Analysis O +
of O +
molecular O +
aberrations O +
of O +
Wnt O +
pathway O +
gladiators O +
in O +
colorectal O +
cancer O +
in O +
the O +
Kashmiri O +
population O -
. O +

The O +
development O +
and O +
progression O +
of O +
colorectal O +
cancer O +
( O -
CRC O -
) O +
is O +
a O +
multi O -
- O -
step O +
process O -
, O +
and O +
the O +
Wnt O +
pathways O +
with O +
its O +
two O +
molecular O +
gladiators O +
adenomatous O +
polyposis O +
coli O +
( O -
APC O -
) O +
and O +
beta O -
- O -
catenin O +
plays O +
an O +
important O +
role O +
in O +
transforming O +
a O +
normal O +
tissue O +
into O +
a O +
malignant O +
one O -
. O +

In O +
this O +
study O -
, O +
we O +
aimed O +
to O +
investigate O +
the O +
role O +
of O +
aberrations O +
in O +
the O +
APC O +
and O +
beta O -
- O -
catenin O +
genes O +
in O +
the O +
pathogenesis O +
of O +
CRC O +
in O +
the O +
Kashmir O +
valley O -
, O +
and O +
to O +
correlate O +
it O +
with O +
various O +
clinicopathological O +
variables O -
. O +

We O +
examined O +
the O +
paired O +
tumour O +
and O +
normal O -
- O -
tissue O +
specimens O +
of O +
86 O +
CRC O +
patients O +
for O +
the O +
occurrence O +
of O +
aberrations O +
in O +
the O +
mutation O +
cluster O +
region O +
( O -
MCR O -
) O +
of O +
the O +
APC O +
gene O +
and O +
exon O +
3 O +
of O +
the O +
beta O -
- O -
catenin O +
gene O +
by O +
polymerase O +
chain O +
reaction O -
- O -
single O -
- O -
strand O +
conformation O +
polymorphism O +
( O -
PCR O -
- O -
SSCP O -
) O +
and/or O +
PCR O -
- O -
direct O +
sequencing O -
. O +

Analysis O +
of O +
promoter O +
hypermethylation O +
of O +
the O +
APC O +
gene O +
was O +
also O +
carried O +
out O +
using O +
methylation O -
- O -
specific O +
PCR O +
( O -
MS O -
- O -
PCR O -
) O -
. O +

The O +
overall O +
mutation O +
rate O +
of O +
the O +
MCR O +
of O +
the O +
APC O +
gene O +
among O +
86 O +
CRC O +
cases O +
was O +
12.8 O +
per O +
cent O +
( O -
11 O +
of O +
86 O -
) O -
. O +

Promoter O +
hypermethylation O +
of O +
APC O +
was O +
observed O +
in O +
54.65 O +
per O +
cent O +
( O -
47 O +
of O +
86 O -
) O +
of O +
cases O -
. O +

Furthermore O -
, O +
we O +
found O +
a O +
significant O +
association O +
between O +
tumour O +
location O -
, O +
tumour O +
grade O +
and O +
node O +
status O +
and O +
the O +
methylation O +
status O +
of O +
the O +
APC O +
gene O +
( O -
p O +
< O -
= O +
0.05 O -
) O -
. O +

Although O +
the O +
number O +
of O +
mutations O +
in O +
the O +
APC O +
and O +
beta O -
- O -
catenin O +
genes O +
in O +
our O +
CRC O +
cases O +
was O +
very O +
low O -
, O +
the O +
study O +
confirms O +
the O +
role O +
of O +
epigenetic O +
gene O +
silencing O +
of O +
the O +
pivotal O +
molecular O +
gladiator O -
, O +
APC O -
, O +
of O +
the O +
Wnt O +
pathway O +
in O +
the O +
development O +
of O +
CRC O +
in O +
the O +
Kashmiri O +
population O -
. O +

IL-17F O +
deficiency O +
inhibits O +
small O +
intestinal O +
tumorigenesis O +
in O +
ApcMin O -
/ O -
+ O +
mice O -
. O +

IL-17 O +
plays O +
an O +
important O +
role O +
in O +
gut O +
homeostasis O -
. O +

However O -
, O +
the O +
role O +
of O +
IL-17F O +
in O +
intestinal O +
tumorigenesis O +
has O +
not O +
been O +
addressed O -
. O +

Here O +
we O +
demonstrate O +
that O +
ablation O +
of O +
IL-17F O +
significantly O +
inhibits O +
spontaneous O +
intestinal O +
tumorigenesis O +
in O +
the O +
small O +
intestine O +
of O +
Apc O -
( O -
Min O -
/ O -
+ O -
) O +
mice O -
. O +

IL-17F O +
ablation O +
decreased O +
IL-1beta O +
and O +
Cox-2 O +
expression O +
as O +
well O +
as O +
IL-17 O +
receptor O +
C O +
( O -
IL-17RC O -
) O +
expression O -
, O +
which O +
were O +
increased O +
in O +
tumors O +
from O +
Apc O -
( O -
Min O -
/ O -
+ O -
) O +
mice O -
. O +

Lack O +
of O +
IL-17F O +
did O +
not O +
reverse O +
the O +
splenomegaly O +
but O +
partially O +
restored O +
thymic O +
atrophy O -
, O +
suggesting O +
a O +
local O +
effect O +
of O +
IL-17F O +
in O +
the O +
intestine O -
. O +

IL-17F O +
deficient O +
Apc O -
( O -
Min O -
/ O -
+ O -
) O +
mice O +
showed O +
a O +
significant O +
decrease O +
in O +
immune O +
cell O +
infiltration O +
in O +
the O +
lamina O +
propria O -
. O +

Interestingly O -
, O +
the O +
expression O +
of O +
IL-17A O +
from O +
CD4 O +
T O +
cells O +
in O +
the O +
lamina O +
propria O +
remains O +
unchanged O +
in O +
the O +
absence O +
of O +
IL-17F O -
. O +

Collectively O -
, O +
our O +
results O +
suggest O +
the O +
proinflammatory O +
and O +
essential O +
role O +
of O +
IL-17F O +
to O +
develop O +
spontaneous O +
intestinal O +
tumorigenesis O +
in O +
Apc O -
( O -
Min O -
/ O -
+ O -
) O +
mice O +
in O +
the O +
presence O +
of O +
IL-17A O -
. O +

Research O +
and O +
discovery O +
of O +
the O +
first O +
human O +
cancer O +
virus O -
, O +
HTLV-1 O -
. O +

Human O +
T O -
- O -
cell O +
lymphoma O +
virus O +
( O -
HTLV O -
) O -
-1 O +
was O +
the O +
first O +
human O +
retrovirus O +
to O +
be O +
discovered O -
. O +

It O +
has O +
been O +
recognized O +
as O +
the O +
cause O +
of O +
adult O +
T O -
- O -
cell O +
leukemia O +
( O -
ATL O -
) O -
. O +

In O +
addition O +
to O +
giving O +
a O +
historical O +
perspective O +
on O +
HTLV-1 O +
and O +
other O +
retrovirus O +
research O -
, O +
this O +
paper O +
discusses O +
the O +
origin O +
of O +
HTLV-1 O -
; O +
the O +
modes O +
of O +
transmission O +
and O +
global O +
epidemiology O +
of O +
HTLV-1 O +
infection O -
; O +
the O +
genome O +
of O +
HTLV-1 O +
and O +
the O +
mechanism O +
of O +
HTLV-1-induced O +
leukemogenesis O -
; O +
the O +
role O +
of O +
HTLV-1 O +
in O +
other O +
diseases O -
, O +
and O +
recent O +
breakthroughs O +
in O +
ATL O +
therapy O -
. O +

Incidence O +
of O +
BRAF O +
p. O +

Val600Glu O +
and O +
p. O +

Val600Lys O +
mutations O +
in O +
a O +
consecutive O +
series O +
of O +
183 O +
metastatic O +
melanoma O +
patients O +
from O +
a O +
high O +
incidence O +
region O -
. O +

AIM O -
: O +
Approximately O +
40 O -
- O -
60 O -
% O +
of O +
melanomas O +
from O +
Caucasian O +
populations O +
carry O +
activating O +
mutations O +
in O +
the O +
BRAF O +
oncogene O -
, O +
with O +
the O +
most O +
common O +
being O +
the O +
p. O +

Val600Glu O +
( O -
V600E O -
) O +
hotspot O +
mutation O +
in O +
exon O +
15 O -
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
frequency O +
of O +
the O +
less O +
common O +
p. O +

Val600Lys O +
( O -
V600 O -
K O -
) O +
mutation O +
in O +
metastatic O +
melanoma O +
from O +
a O +
high O +
incidence O +
region O -
. O +

METHOD O -
: O +
Dideoxy O +
sequencing O +
and O +
fluorescent O +
single O +
strand O +
conformation O +
analysis O +
were O +
used O +
to O +
screen O +
for O +
mutations O +
in O +
exon O +
15 O +
of O +
BRAF O +
in O +
183 O +
cases O +
of O +
metastatic O +
melanoma O -
. O +

RESULTS O -
: O +
The O +
overall O +
incidence O +
of O +
BRAF O +
mutation O +
( O -
89 O -
/ O -
183 O -
, O +
49 O -
% O -
) O +
was O +
very O +
similar O +
to O +
other O +
large O +
studies O +
of O +
Caucasian O +
populations O -
. O +

However O -
, O +
the O +
frequency O +
of O +
the O +
p. O +

Val600Lys O +
mutation O +
was O +
higher O +
than O +
in O +
most O +
other O +
studies O +
and O +
comprised O +
almost O +
one O -
- O -
third O +
of O +
all O +
BRAF O +
mutations O +
in O +
our O +
cohort O +
( O -
27 O -
/ O -
89 O -
, O +
30 O -
% O -
) O -
. O +

CONCLUSION O -
: O +
BRAF O +
p. O +

Val600Lys O +
mutations O +
were O +
present O +
at O +
a O +
relatively O +
high O +
frequency O +
in O +
this O +
cohort O +
of O +
metastatic O +
melanoma O +
patients O +
( O -
27 O -
/ O -
183 O -
, O +
15 O -
% O -
) O -
. O +

Assays O +
used O +
to O +
screen O +
for O +
BRAF O +
mutations O +
in O +
the O +
clinic O +
should O +
be O +
robust O +
enough O +
to O +
detect O +
the O +
p. O +

Val600Lys O +
mutation O -
, O +
as O +
this O +
may O +
have O +
therapeutic O +
implications O -
. O +

Alterations O +
in O +
carbohydrate B-Chemical +
metabolism O +
in O +
canine O +
lymphoma O -
. O +

Following O +
an O +
overnight O +
fast O -
, O +
blood O +
samples O +
were O +
obtained O +
from O +
14 O +
dogs O +
with O +
previously O +
untreated O +
lymphoma O +
before O +
and O +
5 O -
, O +
15 O -
, O +
30 O -
, O +
45 O -
, O +
60 O -
, O +
and O +
90 O +
minutes O +
following O +
an O +
intravenous O +
challenge O +
with O +
500 O +
mg O -
/ O -
kg O +
dextrose B-Chemical -
. O +

Samples O +
were O +
assayed O +
for O +
glucose B-Chemical -
, O +
lactate B-Chemical -
, O +
and O +
insulin O +
concentrations O +
and O +
compared O +
statistically O +
with O +
ten O +
control O +
dogs O +
of O +
similar O +
weight O +
and O +
age O +
undergoing O +
an O +
identical O +
dextrose B-Chemical +
challenge O -
. O +

Dogs O +
with O +
lymphoma O +
had O +
similar O +
glucose B-Chemical +
tolerance O +
curves O +
when O +
compared O +
with O +
controls O -
. O +

Lactate B-Chemical +
concentrations O +
were O +
significantly O +
higher O +
( O -
P O +
less O +
than O +
0.001 O -
) O +
at O +
baseline O +
and O +
all O +
time O +
periods O +
of O +
the O +
glucose B-Chemical +
tolerance O +
test O +
in O +
dogs O +
with O +
lymphoma O +
when O +
compared O +
with O +
controls O -
. O +

Rise O +
in O +
lactate B-Chemical +
concentrations O +
over O +
baseline O +
levels O +
in O +
the O +
first O +
30 O +
minutes O +
of O +
the O +
glucose B-Chemical +
tolerance O +
test O +
were O +
significantly O +
higher O +
in O +
dogs O +
with O +
lymphoma O +
( O -
P O +
= O +
0.011 O -
) O -
. O +

Insulin O +
concentrations O +
were O +
significantly O +
higher O +
( O -
P O +
less O +
than O +
0.001 O -
) O +
at O +
baseline O +
and O +
at O +
the O +
5- O -
, O +
45- O -
, O +
60- O -
, O +
and O +
90-minute O +
time O +
periods O +
of O +
the O +
glucose B-Chemical +
tolerance O +
test O +
in O +
dogs O +
with O +
lymphoma O -
. O +

Rise O +
in O +
insulin O +
concentrations O +
over O +
baseline O +
in O +
the O +
first O +
5 O +
minutes O +
of O +
the O +
glucose B-Chemical +
tolerance O +
test O +
were O +
also O +
significantly O +
greater O +
in O +
dogs O +
with O +
lymphoma O +
( O -
P O +
= O +
0.021 O -
) O -
. O +

These O +
results O +
indicate O +
carbohydrate B-Chemical +
metabolism O +
is O +
altered O +
in O +
dogs O +
with O +
lymphoma O -
. O +

Many O +
of O +
these O +
alterations O +
parallel O +
those O +
observed O +
in O +
human O +
patients O +
suffering O +
from O +
cancer O +
cachexia O +
making O +
canine O +
lymphoma O +
a O +
potential O +
model O +
for O +
further O +
study O +
of O +
the O +
pathogenesis O +
and O +
therapy O +
of O +
cancer O +
cachexia O -
. O +

Identification O +
of O +
a O +
small O +
region O +
of O +
the O +
v O -
- O -
fos O +
gene O +
product O +
that O +
is O +
sufficient O +
for O +
transforming O +
potential O +
and O +
growth O -
- O -
stimulating O +
activity O -
. O +

To O +
analyze O +
the O +
structure O -
- O -
function O +
relationship O +
for O +
the O +
v O -
- O -
fos O +
protein O -
, O +
we O +
constructed O +
in O -
- O -
frame O +
insertion O +
and O +
deletion O +
mutants O +
of O +
the O +
v O -
- O -
fos O +
gene O +
carried O +
by O +
FBJ O -
- O -
MuSV O -
, O +
and O +
expressed O +
them O +
in O +
chicken O +
primary O +
cells O +
using O +
retrovirus O +
vectors O -
. O +

We O +
assessed O +
the O +
effects O +
of O +
these O +
mutations O +
on O +
the O +
ability O +
of O +
the O +
v O -
- O -
fos O +
protein O +
to O +
transform O +
chicken O +
embryo O +
fibroblasts O +
and O +
to O +
stimulate O +
cellular O +
proliferation O +
of O +
chicken O +
neuroretinal O +
cells O -
. O +

The O +
mutant O +
which O +
retains O +
only O +
the O +
central O +
region O +
of O +
the O +
v O -
- O -
fos O +
protein O +
( O -
Met111-Ile206 O -
) O +
have O +
both O +
activities O -
, O +
but O +
the O +
mutants O +
which O +
have O +
deletions O +
in O +
this O +
region O -
, O +
and O +
one O +
of O +
the O +
mutants O +
that O +
has O +
a O +
four O +
amino O +
acid O +
insertion O +
in O +
it O -
, O +
lost O +
both O +
activities O -
. O +

The O +
central O +
region O +
that O +
is O +
sufficient O +
for O +
these O +
activities O +
includes O +
the O +
evolutionarily O +
highly O +
conserved O +
region O +
among O +
human O -
, O +
mouse O +
and O +
chicken O +
c O -
- O -
fos O +
proteins O -
. O +

Additionally O -
, O +
this O +
sequence O +
shares O +
some O +
homology O +
with O +
the O +
DNA O +
binding O +
domain O +
of O +
GCN4 O +
and O +
c O -
- O -
jun O +
protein O -
. O +

The O +
truncated O +
fos O +
protein O +
that O +
contains O +
only O +
part O +
of O +
the O +
central O +
region O +
is O +
not O +
phosphorylated O +
in O +
chicken O +
embryo O +
fibroblasts O -
, O +
indicating O +
that O +
phosphorylation O +
of O +
the O +
fos O +
protein O +
is O +
not O +
necessary O +
for O +
the O +
transforming O +
activity O -
. O +

Low O -
- O -
level O +
X O -
- O -
radiation O +
effects O +
on O +
functional O +
vascular O +
changes O +
in O +
Syrian O +
hamster O +
cheek O +
pouch O +
epithelium O +
during O +
hydrocarbon O +
carcinogenesis O -
. O +

Effects O +
of O +
repeated O +
low O -
- O -
level O +
X O +
radiation O +
on O +
functional O +
microvascular O +
changes O +
in O +
hamster O +
cheek O +
pouch O +
epithelium O +
during O +
and O +
following O +
carcinogenesis O +
by O +
7,12-dimethylbenz B-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
anthracene I-Chemical +
( O -
DMBA B-Chemical -
) O +
were O +
studied O -
. O +

Prior O +
studies O +
showed O +
enhancement O +
of O +
such O +
carcinogenesis O +
by O +
repeated O +
20 O +
rad O +
head O +
and O +
neck O +
X O -
- O -
radiation O +
exposures O -
, O +
and O +
it O +
was O +
proposed O +
that O +
one O +
possible O +
mechanism O +
was O +
radiogenic O +
alteration O +
of O +
the O +
functional O +
microvasculature O +
in O +
a O +
manner O +
which O +
favored O +
subsequent O +
tumor O +
development O -
. O +

Hamsters O +
were O +
treated O +
with O +
either O +
radiation O -
, O +
DMBA B-Chemical -
, O +
radiation O +
+ O +
DMBA B-Chemical -
, O +
or O +
no O +
treatment O -
. O +

Animals O +
were O +
sacrificed O +
at O +
3-week O +
intervals O +
from O +
0 O +
to O +
39 O +
weeks O +
after O +
treatments O +
began O -
. O +

Pouch O +
vascular O +
volume O +
and O +
permeability O +
changes O +
were O +
studied O +
by O +
fractional O +
distributions O +
of O +
radiotracers O +
and O +
were O +
analyzed O +
by O +
a O +
variety O +
of O +
statistical O +
methods O +
which O +
explored O +
the O +
vascular O +
parameters O -
, O +
treatment O +
types O -
, O +
elapsed O +
time O -
, O +
presence O +
of O +
the O +
carcinogen O -
, O +
and O +
histopathologic O +
changes O -
. O +

All O +
treatments O +
resulted O +
in O +
significant O +
changes O +
in O +
vascular O +
volume O +
with O +
time O -
, O +
while O +
only O +
DMBA B-Chemical +
treatments O +
alone O +
resulted O +
in O +
significant O +
changes O +
in O +
vascular O +
permeability O +
with O +
time O -
. O +

Prior O +
to O +
the O +
appearances O +
of O +
frank O +
neoplasms O -
, O +
volumetric O +
changes O +
in O +
DMBA B-Chemical +
only O +
and O +
radiation O +
only O +
groups O +
were O +
similar O -
, O +
while O +
volume O +
changes O +
in O +
DMBA B-Chemical +
+ O +
radiation O +
groups O +
increased O +
slowly O +
to O +
a O +
peak O +
later O +
than O +
in O +
other O +
groups O +
and O +
then O +
declined O +
steadily O +
to O +
levels O +
similar O +
to O +
the O +
radiation O +
only O +
group O -
. O +

As O +
in O +
prior O +
studies O -
, O +
there O +
were O +
significant O +
vascular O +
volume O +
differences O +
between O +
DMBA B-Chemical +
and O +
DMBA B-Chemical +
+ O +
radiation O +
groups O +
of O +
tumor O -
- O -
bearing O +
cheek O +
pouches O -
. O +

DMBA B-Chemical +
maxima O +
were O +
significantly O +
higher O +
than O +
those O +
of O +
DMBA B-Chemical +
+ O +
radiation O -
. O +

Radiation O +
significantly O +
affected O +
DMBA B-Chemical -
- O -
associated O +
vascular O +
volume O +
and O +
permeability O +
changes O +
during O +
carcinogenesis O -
. O +

Several O +
possible O +
explanations O +
for O +
the O +
relationship O +
of O +
these O +
changes O +
to O +
the O +
enhancement O +
of O +
DMBA B-Chemical +
carcinogenesis O +
include O -
: O +
radiation O +
blocking O +
normal O +
capillary O +
proliferative O +
and/or O +
dilatory O +
responses O +
to O +
inflammation O +
secondary O +
to O +
neoplastic O +
changes O -
; O +
radiation O -
- O -
induced O +
focal O +
increases O +
in O +
the O +
pericapillary O +
connective O +
tissue O +
histohematic O +
barrier O -
, O +
stimulating O +
angiogenesis O +
but O +
reducing O +
nutrient O +
diffusion O -
; O +
radiation O +
exposures O +
sensitizing O +
vascular O +
endothelium O +
to O +
subsequent O +
angiogenic O +
stimulation O +
from O +
premalignant O +
tissues O -
; O +
DMBA B-Chemical +
vascular O +
and O +
epithelial O +
effects O +
partially O +
or O +
completely O +
blocking O +
radiation O +
effects O +
on O +
epithelial O +
and/or O +
endothelial O +
cells O -
; O +
and O +
radiation O +
damage O +
to O +
vessel O +
walls O +
partially O +
or O +
fully O +
inhibiting O +
normal O +
physiologic O +
mechanisms O +
of O +
repairing O +
DMBA B-Chemical +
damage O +
to O +
the O +
vessels O -
. O +

Mast O +
cells O +
and O +
tumors O -
. O +

The O +
specific O +
enhancement O +
of O +
tumor O +
proliferation O +
in O +
vitro O -
. O +

Mast O +
cells O +
were O +
found O +
to O +
be O +
unique O +
among O +
the O +
peritoneal O +
leukocytes O +
by O +
virtue O +
of O +
their O +
capacity O +
to O +
enhance O +
profoundly O +
the O +
proliferation O +
of O +
a O +
variety O +
of O +
tumors O +
in O +
vitro O -
. O +

This O +
phenomenon O +
occurs O +
at O +
mast O +
cell O -
/ O -
tumor O +
ratios O +
which O +
reflect O +
the O +
stoichiometry O +
of O +
host O +
cell O -
/ O -
tumor O +
relationships O +
in O +
vivo O -
. O +

The O +
growth O +
factor O +
was O +
found O +
to O +
reside O +
in O +
mast O +
cell O +
granules O +
and O +
was O +
identified O +
as O +
heparin B-Chemical +
by O +
sequential O +
purification O +
and O +
enzymatic O +
degradation O -
. O +

This O +
cellular O +
interaction O +
was O +
tumor O -
- O -
specific O -
, O +
although O +
isolated O +
granules O +
could O +
enhance O +
fibroblast O +
proliferation O -
. O +

The O +
findings O +
are O +
discussed O +
in O +
relation O +
to O +
previous O +
morphologic O +
studies O -
, O +
reports O +
of O +
in O +
vitro O +
mast O -
- O -
cell O -
- O -
mediated O +
tumor O +
cytotoxicity O -
, O +
and O +
the O +
role O +
of O +
mast O +
cells O +
in O +
angiogenesis O +
and O +
connective O +
tissue O +
proliferation O -
. O +

Participation O +
of O +
p53 O +
cellular O +
tumour O +
antigen O +
in O +
transformation O +
of O +
normal O +
embryonic O +
cells O -
. O +

The O +
cellular O +
tumour O +
antigen O +
p53 O +
is O +
found O +
at O +
elevated O +
levels O +
in O +
a O +
wide O +
variety O +
of O +
transformed O +
cells O +
( O -
for O +
reviews O +
see O +
refs O +
1 O -
, O +
2 O -
) O -
. O +

Very O +
little O +
is O +
yet O +
known O +
about O +
the O +
precise O +
relationship O +
of O +
p53 O +
to O +
malignant O +
transformation O -
. O +

Although O +
the O +
increase O +
in O +
p53 O +
levels O +
could O +
be O +
a O +
secondary O +
by O -
- O -
product O +
of O +
the O +
transformed O +
state O -
, O +
it O +
is O +
equally O +
possible O +
that O +
p53 O +
is O +
actively O +
involved O +
in O +
altering O +
cellular O +
growth O +
properties O -
, O +
especially O +
as O +
it O +
has O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
normal O +
cell O +
proliferation O -
. O +

We O +
sought O +
to O +
test O +
whether O +
p53 O +
could O +
behave O +
in O +
a O +
manner O +
similar O +
to O +
known O +
genes O +
in O +
a O +
biological O +
test O +
system O -
, O +
and O +
we O +
demonstrate O +
here O +
that O +
p53 O +
can O +
cooperate O +
with O +
the O +
activated O +
Ha O -
- O -
ras O +
oncogene O +
to O +
transform O +
normal O +
embryonic O +
cells O -
. O +

The O +
resultant O +
foci O +
contain O +
cells O +
of O +
a O +
markedly O +
altered O +
morphology O +
which O +
produce O +
high O +
levels O +
of O +
p53 O -
. O +

Cell O +
lines O +
established O +
from O +
such O +
foci O +
elicit O +
tumours O +
in O +
syngeneic O +
animals O -
. O +

Cells O +
transformed O +
by O +
Rous O +
sarcoma O +
virus O +
release O +
transforming O +
growth O +
factors O -
. O +

Chicken O +
embryo O +
fibroblasts O +
and O +
hamster O +
BHK O +
cells O +
transformed O +
by O +
Rous O +
sarcoma O +
virus O +
( O -
RSV O -
) O +
release O +
in O +
their O +
culture O +
media O +
growth O +
factors O +
which O +
enhance O +
markedly O +
anchorage O -
- O -
independent O +
colony O +
formation O +
in O +
gelified O +
medium O -
, O +
at O +
the O +
restrictive O +
temperature O +
( O -
41 O +
degrees O +
5 O +
C O -
) O -
, O +
of O +
chicken O +
embryo O +
fibroblasts O +
( O -
CEF O -
) O +
infected O +
by O +
RSV O +
mutants O +
with O +
a O +
ts O +
mutation O +
of O +
the O +
src O +
gene O -
. O +

This O +
action O +
is O +
not O +
observed O +
with O +
uninfected O +
CEF O -
, O +
and O -
, O +
therefore O -
, O +
appears O +
to O +
require O +
some O +
expression O +
of O +
the O +
viral O +
src O +
gene O +
in O +
the O +
target O +
cells O -
. O +

The O +
enhancing O +
factors O +
are O +
proteins O +
related O +
to O +
the O +
family O +
of O +
the O +
transforming O +
growth O +
factors O +
( O -
TGFs O -
) O +
by O +
their O +
molecular O +
weight O +
( O -
about O +
20 O +
kd O -
) O -
, O +
their O +
heat O +
and O +
acid O +
resistance O -
, O +
and O +
their O +
sensitivity O +
to O +
dithiothreitol B-Chemical -
. O +

They O +
do O +
not O +
compete O +
with O +
125I O +
EGF O +
for O +
binding O +
on O +
the O +
EGF O +
receptors O +
of O +
the O +
membrane O +
of O +
A431 O +
cells O -
. O +

As O +
chicken O +
embryo O +
fibroblasts O +
are O +
devoid O +
of O +
EGF O +
receptors O -
, O +
their O +
activity O +
is O +
not O +
potentiated O +
by O +
EGF O -
. O +

Effects O +
of O +
3-chloromethylthiochromone-1,1-dioxide B-Chemical +
on O +
nucleic B-Chemical +
acid I-Chemical -
, O +
protein O -
, O +
and O +
aerobic O +
and O +
anaerobic O +
metabolism O +
of O +
Ehrlich O +
ascites O +
tumor O +
cells O -
. O +

3-Chloromethylthiochromone-1,1-dioxide B-Chemical +
was O +
observed O +
to O +
be O +
a O +
potent O +
inhibitor O +
of O +
Ehrlich O +
ascites O +
carcinoma O +
growth O +
and O +
a O +
moderate O +
inhibitor O +
of O +
P-388 O +
lymphocytic O +
leukemia O +
growth O +
at O +
10 O +
mg O -
/ O -
kg O -
/ O -
day O -
. O +

Preliminary O +
in O +
vitro O +
studies O +
showed O +
that O +
the O +
agents O +
significantly O +
inhibited O +
RNA B-Chemical +
and O +
DNA O +
synthesis O +
in O +
Ehrlich O +
ascites O +
cells O -
. O +

In O +
vivo O +
studies O +
after O +
dosing O +
on O +
Days O +
6 O -
, O +
7 O -
, O +
and O +
8 O +
demonstrated O +
the O +
same O +
reductions O +
in O +
nucleic B-Chemical +
acid I-Chemical +
synthesis O +
and O +
a O +
moderate O +
reduction O +
in O +
protein O +
synthesis O -
. O +

The O +
primary O +
site O +
of O +
nucleic B-Chemical +
acid I-Chemical +
synthesis O -
, O +
which O +
was O +
blocked O +
by O +
3-chloromethylthiochromone B-Chemical -
, O +
was O +
at O +
orotidine O +
monophosphate O +
decarboxylase O +
in O +
the O +
primidine B-Chemical +
pathway O -
. O +

Other O +
enzymes O -
, O +
in O +
anaerobic O +
and O +
aerobic O +
glycolysis O -
, O +
which O +
were O +
blocked O +
include O +
hexokinase O -
, O +
phosphofructokinase O -
, O +
succinic O +
and O +
alpha O -
- O -
ketoglutarate O +
dehydrogenases O -
, O +
as O +
well O +
as O +
States O +
3 O +
and O +
4 O +
of O +
oxidative O +
phosphorylation O -
. O +

Suppressed O +
transformation O +
and O +
induced O +
differentiation O +
of O +
HER-2 O -
/ O -
neu O -
- O -
overexpressing O +
breast O +
cancer O +
cells O +
by O +
emodin B-Chemical -
. O +

The O +
amplification O +
and O +
overexpression O +
of O +
the O +
HER-2 O -
/ O -
neu O +
proto O -
- O -
oncogene O -
, O +
which O +
encodes O +
the O +
tyrosine O +
kinase O +
receptor O +
p185neu O -
, O +
have O +
been O +
observed O +
frequently O +
in O +
tumors O +
from O +
human O +
breast O +
cancer O +
patients O +
and O +
are O +
correlated O +
with O +
poor O +
prognosis O -
. O +

To O +
explore O +
the O +
potential O +
of O +
chemotherapy O +
directed O +
at O +
the O +
tyrosine O +
kinase O +
of O +
p185neu O -
, O +
we O +
have O +
found O +
that O +
emodin B-Chemical +
( O -
3-methyl-1,6,8-trihydroxyanthraquinone B-Chemical -
) O -
, O +
a O +
tyrosine O +
kinase O +
inhibitor O -
, O +
suppresses O +
autophosphorylation O +
and O +
transphosphorylation O +
activities O +
of O +
HER-2 O -
/ O -
neu O +
tyrosine O +
kinase O -
, O +
resulting O +
in O +
tyrosine O +
hypophosphorylation O +
of O +
p185neu O +
in O +
HER-2 O -
/ O -
neu O -
- O -
overexpressing O +
breast O +
cancer O +
cells O -
. O +

Emodin B-Chemical -
, O +
at O +
a O +
40-microM O +
concentration O -
, O +
which O +
repressed O +
tyrosine O +
kinase O +
of O +
p185neu O -
, O +
efficiently O +
inhibited O +
both O +
anchorage O -
- O -
dependent O +
and O +
anchorage O -
- O -
independent O +
growth O +
of O +
HER-2 O -
/ O -
neu O -
- O -
overexpressing O +
breast O +
cancer O +
cells O -
. O +

However O -
, O +
the O +
inhibition O +
was O +
much O +
less O +
effective O +
for O +
those O +
cells O +
expressing O +
basal O +
levels O +
of O +
p185neu O +
under O +
the O +
same O +
conditions O -
. O +

Emodin B-Chemical +
also O +
induced O +
differentiation O +
of O +
HER-2 O -
/ O -
neu O -
- O -
overexpressing O +
breast O +
cancer O +
cells O +
by O +
exhibiting O +
a O +
morphological O +
maturation O +
property O +
of O +
large O +
lacy O +
nuclei O +
surrounded O +
by O +
sizable O +
flat O +
cytoplasm O +
and O +
by O +
showing O +
a O +
measurable O +
production O +
of O +
large O +
lipid B-Chemical +
droplets O -
, O +
which O +
is O +
a O +
marker O +
of O +
mature O +
breast O +
cells O -
. O +

Therefore O -
, O +
our O +
results O +
indicate O +
that O +
emodin B-Chemical +
inhibits O +
HER-2 O -
/ O -
neu O +
tyrosine O +
kinase O +
activity O +
and O +
preferentially O +
suppresses O +
growth O +
and O +
induces O +
differentiation O +
of O +
HER-2 O -
/ O -
neu O -
- O -
overexpressing O +
cancer O +
cells O -
. O +

These O +
results O +
may O +
have O +
chemotherapeutic O +
implications O +
for O +
using O +
emodin B-Chemical +
to O +
target O +
HER-2 O -
/ O -
neu O -
- O -
overexpressing O +
cancer O +
cells O -
. O +

Cancer O +
metastasis O -
: O +
negative O +
regulation O +
by O +
an O +
invasion O -
- O -
suppressor O +
complex O -
. O +

Invasion O +
is O +
the O +
hallmark O +
of O +
tumor O +
malignancy O -
. O +

We O +
situate O +
invasion O +
within O +
microecosystems O +
comprising O +
neoplastic O +
cells O +
as O +
well O +
as O +
host O +
cells O -
. O +

Modulation O +
of O +
invasion O +
within O +
such O +
systems O +
is O +
ascribed O +
to O +
balances O +
between O +
promoter O +
and O +
suppressor O +
pathways O -
. O +

The O +
E O -
- O -
cadherin O -
/ O -
alpha- O -
, O +
beta- O -
, O +
gamma O -
- O -
catenin O +
complex O +
has O +
an O +
invasion O -
- O -
suppressor O +
function O +
as O +
evidenced O +
by O +
transfections O +
either O +
with O +
sense O +
cDNA O +
encoding O +
these O +
molecules O +
or O +
with O +
antisense O +
cDNA O +
inhibiting O +
their O +
expression O -
. O +

Loss O +
of O +
heterozygosity O +
at O +
the O +
E O -
- O -
Cadherin O +
( O -
uvo O -
) O +
locus O +
has O +
been O +
reported O -
, O +
but O +
mutations O +
in O +
the O +
E O -
- O -
cadherin O +
gene O +
seem O +
to O +
be O +
rare O -
. O +

Downregulation O +
of O +
E O -
- O -
cadherin O +
occurred O +
at O +
the O +
level O +
of O +
transcription O +
or O +
of O +
mRNA O +
stability O -
. O +

Ex O +
vivo O +
cultures O +
from O +
invasive O +
tumors O +
or O +
metastases O +
produced O +
cells O +
that O +
were O +
homogeneously O +
E O -
- O -
cadherin O -
- O -
positive O +
and O +
noninvasive O +
in O +
vitro O -
. O +

These O +
observations O +
have O +
led O +
to O +
the O +
idea O +
that O +
factors O +
in O +
the O +
host O +
downmodulate O +
the O +
E O -
- O -
cadherin O +
complex O +
and O +
promote O +
invasion O +
most O +
probably O +
in O +
a O +
transient O +
way O -
. O +

Heparin B-Chemical -
- O -
steroid B-Chemical +
conjugates O -
: O +
new O +
angiogenesis O +
inhibitors O +
with O +
antitumor O +
activity O +
in O +
mice O -
. O +

Inhibitors O +
of O +
angiogenesis O +
hold O +
potential O +
in O +
the O +
treatment O +
of O +
cancer O +
and O +
other O +
diseases O +
where O +
the O +
disease O +
is O +
caused O +
or O +
maintained O +
by O +
the O +
inappropriate O +
growth O +
of O +
blood O +
vessels O -
. O +

In O +
the O +
present O +
study O -
, O +
a O +
novel O +
inhibitor O +
of O +
angiogenesis O +
was O +
synthesized O +
by O +
covalently O +
linking O +
a O +
nonanticoagulating O +
derivative O +
of O +
heparin B-Chemical -
, O +
heparin B-Chemical +
adipic I-Chemical +
hydrazide I-Chemical +
( O -
HAH B-Chemical -
) O -
, O +
by O +
an O +
acid O -
- O -
labile O +
bond O +
to O +
the O +
antiangiogenic O +
steroid B-Chemical -
, O +
cortisol B-Chemical -
. O +

The O +
rationale O +
was O +
that O +
the O +
heparin B-Chemical +
derivative O -
, O +
which O +
binds O +
to O +
sulfated O +
polyanion O +
receptors O +
on O +
endothelial O +
cells O -
, O +
should O +
concentrate O +
the O +
steroid B-Chemical +
on O +
the O +
surface O +
of O +
vascular O +
endothelial O +
cells O -
. O +

Endocytosis O +
of O +
the O +
conjugate O +
and O +
decomposition O +
of O +
the O +
acid O -
- O -
labile O +
linkage O +
inside O +
lysosomes O +
and O +
other O +
acidic O +
intracellular O +
compartments O +
should O +
then O +
lead O +
to O +
release O +
of O +
the O +
cortisol B-Chemical +
and O +
expression O +
of O +
its O +
antiproliferative O +
activity O -
. O +

Analysis O +
of O +
the O +
stability O +
of O +
HAH B-Chemical -
- I-Chemical -
cortisol I-Chemical +
showed O +
that O +
it O +
was O +
stable O +
at O +
pH O +
7.4 O +
and O +
broke O +
down O +
rapidly O +
( O -
t1 O -
/ O -
2 O +
15 O +
min O -
) O +
at O +
pH O +
4.8 O +
at O +
37 O +
degrees O +
C. O +
Treatment O +
of O +
murine O +
pulmonary O +
capillary O +
endothelial O +
cells O +
with O +
HAH B-Chemical -
- I-Chemical -
cortisol I-Chemical +
at O +
10 O -
( O -
-5 O -
) O +
M O +
( O -
with O +
respect O +
to O +
cortisol B-Chemical -
) O +
suppressed O +
their O +
DNA O +
synthesis O +
by O +
50 O -
% O +
and O +
inhibited O +
their O +
migration O +
into O +
wounded O +
areas O +
of O +
confluent O +
monolayers O -
. O +

HAH B-Chemical -
- I-Chemical -
cortisol I-Chemical +
at O +
10 O -
( O -
-4 O -
) O +
M O +
( O -
with O +
respect O +
to O +
cortisol B-Chemical -
) O +
did O +
not O +
suppress O +
the O +
DNA O +
synthesis O +
of O +
Lewis O +
lung O +
carcinoma O +
cells O -
. O +

Daily O +
i.p O -
. O +

injections O +
of O +
HAH B-Chemical -
- I-Chemical -
cortisol I-Chemical +
into O +
mice O +
bearing O +
s.c O -
. O +

sponge O +
implants O +
retarded O +
vascularization O +
of O +
the O +
sponge O -
, O +
and O +
injections O +
directly O +
into O +
the O +
sponge O +
abolished O +
vascularization O +
for O +
as O +
long O +
as O +
the O +
injections O +
were O +
continued O -
. O +

Daily O +
i.v O -
. O +

injections O +
of O +
HAH B-Chemical -
- I-Chemical -
cortisol I-Chemical +
at O +
doses O +
causing O +
no O +
apparent O +
toxicity O +
retarded O +
the O +
growth O +
of O +
solid O +
s.c O -
. O +

Lewis O +
lung O +
carcinomas O +
in O +
mice O +
by O +
up O +
to O +
65 O -
% O -
. O +

In O +
all O +
of O +
these O +
assays O -
, O +
equivalent O +
treatments O +
with O +
a O +
mixture O +
of O +
the O +
HAH B-Chemical +
plus O +
cortisol B-Chemical +
was O +
significantly O +
less O +
effective O -
. O +

The O +
antiproliferative O +
effect O +
of O +
HAH B-Chemical -
- I-Chemical -
cortisol I-Chemical +
on O +
endothelial O +
cells O +
appeared O +
independent O +
of O +
the O +
glucocorticoid B-Chemical +
activity O +
of O +
the O +
steroid B-Chemical +
since O +
HAH B-Chemical +
conjugated O +
to O +
5 B-Chemical +
beta I-Chemical -
- I-Chemical -
pregnane-3 I-Chemical +
alpha,17 I-Chemical +
alpha,21-triol-20-one I-Chemical -
, O +
a O +
steroid B-Chemical +
lacking O +
glucocorticoid B-Chemical +
or O +
mineralocorticoid B-Chemical +
activity O -
, O +
was O +
even O +
more O +
effective O +
at O +
inhibiting O +
DNA O +
synthesis O +
by O +
murine O +
pulmonary O +
capillary O +
endothelial O +
cells O +
than O +
was O +
HAH B-Chemical -
- I-Chemical -
cortisol I-Chemical -
. O +

In O +
conclusion O -
, O +
HAH B-Chemical -
- I-Chemical -
cortisol I-Chemical +
represents O +
the O +
prototype O +
of O +
a O +
new O +
class O +
of O +
angiogenesis O +
inhibitors O +
for O +
the O +
treatment O +
of O +
cancer O +
and O +
other O +
angiogenic O +
diseases O -
. O +

Syndecan-1 O +
expression O +
in O +
mammary O +
epithelial O +
tumor O +
cells O +
is O +
E O -
- O -
cadherin O -
- O -
dependent O -
. O +

E O -
- O -
cadherin O +
is O +
a O +
Ca B-Chemical -
( I-Chemical -
2+ I-Chemical -
) I-Chemical -
-dependent O +
cell O -
- O -
cell O +
adhesion O +
molecule O -
, O +
which O +
is O +
mainly O +
expressed O +
in O +
epithelial O +
cells O -
. O +

Recent O +
studies O +
have O +
shown O +
that O +
E O -
- O -
cadherin O +
has O +
an O +
important O +
role O +
as O +
an O +
invasion O +
suppressor O +
molecule O +
in O +
epithelial O +
tumor O +
cells O -
. O +

Syndecan-1 O +
is O +
a O +
cell O +
surface O +
proteoglycan O +
that O +
has O +
been O +
implicated O +
in O +
a O +
number O +
of O +
cellular O +
functions O +
including O +
cell O -
- O -
cell O +
adhesion O -
, O +
cell O -
- O -
matrix O +
anchorage O +
and O +
growth O +
factor O +
presentation O +
for O +
signalling O +
receptors O -
. O +

Its O +
suppression O +
has O +
also O +
been O +
shown O +
to O +
be O +
associated O +
with O +
malignant O +
transformation O +
of O +
epithelial O +
cells O -
. O +

In O +
order O +
to O +
better O +
understand O +
the O +
coordinated O +
regulation O +
of O +
cell O -
- O -
cell O +
and O +
cell O -
- O -
matrix O +
interactions O +
during O +
malignant O +
transformation O -
, O +
we O +
have O +
studied O +
the O +
expression O +
of O +
syndecan-1 O +
in O +
malignant O +
mammary O +
tumor O +
cells O +
genetically O +
manipulated O +
for O +
E O -
- O -
cadherin O +
expression O -
. O +

In O +
invasive O +
NM O -
- O -
e O -
- O -
ras O -
- O -
MAC1 O +
cells O -
, O +
where O +
E O -
- O -
cadherin O +
was O +
partially O +
downregulated O +
by O +
specific O +
antisense O +
RNA O -
, O +
syndecan-1 O +
expression O +
was O +
suppressed O -
. O +

Furthermore O -
, O +
transfection O +
of O +
E O -
- O -
cadherin O +
cDNA O +
into O +
invasive O +
NM O -
- O -
f O -
- O -
ras O -
- O -
TD O +
cells O +
resulted O +
in O +
the O +
upregulation O +
of O +
syndecan-1 O +
expression O +
in O +
association O +
with O +
decreased O +
invasiveness O -
. O +

In O +
both O +
cases O -
, O +
regulation O +
of O +
syndecan-1 O +
occurred O +
post O -
- O -
transcriptionally O -
, O +
since O +
syndecan-1 O +
mRNA O +
levels O +
remained O +
unchanged O -
. O +

Instead O -
, O +
a O +
translational O +
regulation O +
is O +
suggested O -
, O +
since O +
syndecan-1 O +
core O +
protein O +
synthesis O +
was O +
E O -
- O -
cadherin O +
dependent O -
. O +

Another O +
cell O +
adhesion O +
protein O -
, O +
beta O +
1-integrin O +
was O +
not O +
affected O +
by O +
E O -
- O -
cadherin O +
expression O -
. O +

The O +
data O +
provide O +
an O +
example O +
of O +
coordinated O +
changes O +
in O +
the O +
expression O +
of O +
two O +
cell O +
adhesion O +
molecules O -
, O +
syndecan-1 O +
and O +
E O -
- O -
cadherin O +
during O +
epithelial O +
cell O +
transformation O -
. O +

Comparison O +
of O +
transformation O +
by O +
manganese B-Chemical +
sulfate I-Chemical +
and O +
5-azacytidine B-Chemical +
in O +
Rat O +
6 O +
cells O +
overexpressing O +
the O +
c O -
- O -
myc O +
oncogene O -
. O +

Rat O +
6 O +
cells O +
are O +
not O +
transformed O +
by O +
treatment O +
with O +
the O +
well O -
- O -
known O +
carcinogens O +
benzo B-Chemical -
[ I-Chemical -
a I-Chemical -
] I-Chemical -
pyrene I-Chemical +
( O -
BP B-Chemical -
) O +
or O +
N B-Chemical -
- I-Chemical -
methyl I-Chemical -
- I-Chemical -
N I-Chemical -
- I-Chemical -
nitro I-Chemical -
- I-Chemical -
N'-nitrosoguanidine I-Chemical +
( O -
MNNG B-Chemical -
) O -
. O +

Upon O +
retroviral O +
transduction O +
of O +
the O +
mouse O +
c O -
- O -
myc O +
gene O -
, O +
Rat O +
6 O +
cells O +
showed O +
mildly O +
altered O +
morphology O +
and O +
formed O +
microcolonies O +
in O +
soft O +
agar O -
; O +
furthermore O -
, O +
they O +
could O +
be O +
transformed O +
by O +
BP B-Chemical +
and O +
MNNG B-Chemical +
to O +
form O +
large O +
colonies O +
in O +
agar O +
( O -
Hsiao O +
et O +
al. O +
( O -
1992 O -
) O +
Mol O -
. O +

Carcinogenesis O -
, O +
5 O -
, O +
140 O -
- O -
154 O -
) O -
. O +

In O +
the O +
current O +
report O -
, O +
we O +
tested O +
the O +
sensitivity O +
of O +
the O +
c O -
- O -
myc O -
- O -
overexpressing O +
cells O +
( O -
Rat O +
6 O -
/ O -
c O -
- O -
myc O -
) O +
to O +
two O +
additional O +
chemicals O -
: O +
5-azacytidine B-Chemical +
and O +
MnSO4 B-Chemical -
. O +

These O +
chemicals O +
differ O +
from O +
the O +
direct O -
- O -
acting O +
mutagens O +
tested O +
previously O -
. O +

5-Azacytidine B-Chemical -
, O +
a O +
potent O +
DNA O +
methylation O +
inhibitor O -
, O +
induced O +
growth O +
of O +
large O +
colonies O +
in O +
soft O +
agar O +
cultures O +
of O +
Rat O +
6 O +
or O +
Rat O +
6 O -
/ O -
c O -
- O -
myc O +
cells O -
. O +

On O +
the O +
other O +
hand O -
, O +
MnSO4 B-Chemical +
only O +
induced O +
transformation O +
in O +
Rat O +
6 O -
/ O -
c O -
- O -
myc O +
cells O -
, O +
but O +
not O +
the O +
parental O +
Rat O +
6 O +
cells O -
. O +

Transformants O +
induced O +
by O +
5-azacytidine B-Chemical +
lost O +
c O -
- O -
myc O -
- O -
induced O +
apoptotic O +
cell O +
death O -
, O +
whereas O +
MnSO4-induced B-Chemical +
transformants O +
showed O +
a O +
higher O +
degree O +
of O +
apoptosis O +
than O +
the O +
parental O +
Rat O +
6 O -
/ O -
c O -
- O -
myc O +
cells O -
. O +

These O +
results O +
suggest O +
that O +
MnSO4 B-Chemical +
co O -
- O -
operates O +
with O +
overexpressed O +
c O -
- O -
myc O +
in O +
inducing O +
transformation O -
, O +
while O +
5-azacytidine B-Chemical +
transformation O +
is O +
independent O +
of O +
c O -
- O -
myc O +
overexpression O +
and O +
may O +
involve O +
alterations O +
in O +
the O +
regulation O +
of O +
apoptosis O -
. O +

Prophylactic O +
thyroidectomy O +
in O +
MEN O +
IIA O -
: O +
does O +
the O +
calcitonin O +
level O +
correlate O +
with O +
tumor O +
spread O -
? O +

BACKGROUND O -
: O +
The O +
fate O +
of O +
patients O +
with O +
multiple O +
endocrine O +
neoplasia O +
of O +
type O +
II O +
A O +
( O -
MEN O +
II O +
A O -
) O +
is O +
determined O +
by O +
medullary O +
thyroid O +
carcinoma O -
, O +
which O +
occurs O +
in O +
all O +
cases O -
. O +

This O +
has O +
led O +
to O +
the O +
therapeutic O +
concept O +
of O +
prophylactic O +
thyroidectomy O +
in O +
affected O +
family O +
members O +
with O +
the O +
goal O +
of O +
removing O +
the O +
thyroid O +
before O +
the O +
manifestation O +
of O +
carcinoma O -
. O +

We O +
investigated O +
a O +
prophylactically O +
thyroidectomized O +
MEN O +
II O +
A O +
population O +
to O +
determine O +
whether O +
the O +
highly O +
specific O +
and O +
sensitive O +
tumor O +
marker O +
calcitonin O +
correlates O +
with O +
tumor O +
spread O -
. O +

PATIENTS O +
AND O +
METHODS O -
: O +
Fifteen O +
patients O +
with O +
MEN O +
II O +
A O +
( O -
aged O +
4 O -
- O -
24 O +
years O -
) O +
who O +
had O +
undergone O +
prophylactic O +
thyroidectomy O +
since O +
1990 O +
were O +
included O +
in O +
the O +
study O -
. O +

Baseline O +
and O +
pentagastrin B-Chemical -
- O -
stimulated O +
calcitonin O +
levels O +
were O +
preoperatively O +
determined O +
in O +
all O +
cases O -
. O +

The O +
indication O +
for O +
surgery O +
was O +
established O +
on O +
the O +
basis O +
of O +
pathologic O +
calcitonin O +
levels O +
in O +
the O +
first O +
seven O +
patients O +
and O +
on O +
the O +
basis O +
of O +
detected O +
RET O +
proto O -
- O -
oncogene O +
mutation O +
in O +
the O +
other O +
eight O +
patients O -
. O +

Bilateral O +
central O +
lymphadenectomy O +
was O +
performed O +
in O +
all O +
patients O +
in O +
addition O +
to O +
thyroidectomy O -
. O +

RESULTS O -
: O +
Histology O +
demonstrated O +
C O -
- O -
cell O +
hyperplasia O +
in O +
five O +
patients O +
( O -
aged O +
4 O -
- O -
13 O +
years O -
) O -
, O +
unilateral O +
medullary O +
microcarcinoma O +
in O +
six O +
( O -
aged O +
9 O -
- O -
17 O +
years O -
) O +
and O +
a O +
bilateral O +
medullary O +
microcarcinoma O +
in O +
three O +
cases O +
( O -
aged O +
17 O -
- O -
24 O +
years O -
) O -
. O +

One O +
9-year O -
- O -
old O +
boy O +
with O +
bilateral O +
microcarcinoma O +
already O +
had O +
a O +
lymph O +
node O +
metastasis O -
. O +

The O +
mean O +
baseline O +
calcitonin O +
level O +
correlated O +
with O +
the O +
histologic O +
findings O +
( O -
r=0.71 O -
, O +
P=0.003 O -
) O +
but O +
there O +
was O +
no O +
correlation O +
between O +
pentagastrin B-Chemical -
- O -
stimulated O +
calcitonin O +
levels O +
and O +
histology O +
( O -
r=0.21 O -
, O +
P=0.47 O -
) O -
. O +

CONCLUSION O -
: O +
In O +
MEN O +
II O +
A O +
patients O +
undergoing O +
prophylactic O +
thyroidectomy O -
, O +
baseline O +
but O +
not O +
stimulated O +
calcitonin O +
levels O +
already O +
correlate O +
with O +
the O +
histologic O +
tumor O +
stage O +
at O +
the O +
stage O +
of O +
clinically O +
occult O +
C O -
- O -
cell O +
hyperplasia O +
or O +
medullary O +
microcarcinoma O -
. O +

However O -
, O +
biochemical O +
screening O +
can O -
not O +
reliably O +
discriminate O +
the O +
transition O +
from O +
C O -
- O -
cell O +
hyperplasia O +
to O +
invasive O +
microcarcinoma O -
. O +

Individuals O +
with O +
MEN O +
IIA O +
should O +
therefore O +
undergo O +
early O +
prophylactic O +
thyroidectomy O +
once O +
the O +
diagnosis O +
is O +
confirmed O +
by O +
molecular O +
genetic O +
testing O -
. O +

